var title_f5_11_5296="Parasternal short axis TTE I";
var content_f5_11_5296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Parasternal short axis view of aortic valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 171px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal short axis view from a transthoracic echocardiogram shows the noncoronary (NCC), right coronary (RCC) and left coronary (LCC) leaflets of the aortic valve. Also seen are the left atrium (LA), right atrium (RA), tricuspid valve (TV), right ventricle (RV) and pulmonic valve (PV).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5296=[""].join("\n");
var outline_f5_11_5296=null;
var title_f5_11_5297="Dimemorfan: International drug information";
var content_f5_11_5297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dimemorfan: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Astomin (JP);",
"     </li>",
"     <li>",
"      Dastosin (ES);",
"     </li>",
"     <li>",
"      Gentus (IT);",
"     </li>",
"     <li>",
"      Tusben (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Dimemorfan Phosphate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitussive",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 10-20 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Solution, oral: 10 mg/5 mL (150 mL, 250 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10368 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5297=[""].join("\n");
var outline_f5_11_5297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303755\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978556\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978558\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978557\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821104\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978560\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10368\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10368|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_11_5298="Cupping";
var content_f5_11_5298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cupping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cupping is used in Middle Eastern, Asian, Latin American, and Eastern European cultures as a means to \"draw out\" various ailments. Alcohol is placed in a small cup and ignited; the heated cup is then applied to the skin, resulting in circular burns. Central ecchymosis or petechiae result from the suction effect of the heated air as it cools and contracts",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jan E Drutz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5298=[""].join("\n");
var outline_f5_11_5298=null;
var title_f5_11_5299="Levofloxacin (ophthalmic): Pediatric drug information";
var content_f5_11_5299=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levofloxacin (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37043?source=see_link\">",
"    see \"Levofloxacin (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/63/24564?source=see_link\">",
"    see \"Levofloxacin (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8398379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iquix&reg;;",
"     </li>",
"     <li>",
"      Quixin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10501810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37043?source=see_link\">",
"      see \"Levofloxacin (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;1 year and Adults: Bacterial conjunctivitis: 0.5% solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment day 1 and day 2: Instill 1-2 drops into affected eye(s) every 2 hours while awake, up to 8 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment day 3-7: Instill 1-2 drops into affected eye(s) every 4 hours while awake, up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;6 years and Adults: Bacterial corneal ulcer: 1.5% solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment days 1-3: Instill 1-2 drops into affected eye(s) every 30 minutes to 2 hours while awake and ~4 and 6 hours after retiring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment day 4 through treatment completion: Instill 1-2 drops into affected eye(s) every 1-4 hours while awake",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8408140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iquix&reg;: 1.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quixin&reg;: 0.5% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8398381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10501811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for subconjunctival injection or for use into anterior chamber of the eye. Contact lenses should not be worn during treatment. Instill drops into conjunctival sac of affected eye(s); apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects; avoid contacting bottle tip with skin",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10501808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10501765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used ophthalmically for treatment of bacterial conjunctivitis due to",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-susceptible strains),",
"     <i>",
"      S. epidermidis",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      Streptococcus",
"     </i>",
"     (groups C/F),",
"     <i>",
"      Streptococcus",
"     </i>",
"     (group G), Viridans group",
"     <i>",
"      Streptococci",
"     </i>",
"     ,",
"     <i>",
"      Corynebacterium",
"     </i>",
"     spp,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      Acinetobacter",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8398369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Levofloxacin may be confused with levETIRAcetam, levodopa, levothyroxine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8404714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Taste disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Decreased vision (transient), foreign body sensation, ocular pain or discomfort, photophobia, transient ocular burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, lid edema, ocular dryness, ocular itching",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10501806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levofloxacin, any component, or other quinolones",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10903474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy (primarily with systemic use). Prolonged use may result in fungal or bacterial superinfection.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10903473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There have been reports of tendon inflammation and/or rupture with systemic quinolone antibiotics. Exposure following ophthalmic administration is substantially lower than with systemic therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8404717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8400760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8400761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies levofloxacin ophthalmic as pregnancy category C. When administered orally or I.V., levofloxacin crosses the placenta. Refer to the Levofloxacin (Systemic) monograph for details. The amount of levofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral or I.V. doses.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10501809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     L-isomer of the racemate, ofloxacin, levofloxacin inhibits DNA gyrase (bacterial topoisomerase II), thereby inhibiting relaxation of supercoiled DNA and promoting breakage of DNA strands. DNA gyrase maintains the superhelical structure of DNA and is required for DNA replication, transcription, repair, recombination, and transposition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10903475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Only small amounts are absorbed systemically after ophthalmic instillation.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16012 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5299=[""].join("\n");
var outline_f5_11_5299=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398379\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501764\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501810\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8408140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398381\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501811\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501808\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501765\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398369\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404714\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501806\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10903474\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10903473\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299594\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404717\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400760\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400761\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501809\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10903475\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16012\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16012|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37043?source=related_link\">",
"      Levofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/63/24564?source=related_link\">",
"      Levofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16521?source=related_link\">",
"      Levofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/32/13830?source=related_link\">",
"      Levofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23768?source=related_link\">",
"      Levofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_11_5300="Irritant contact dermatitis 2";
var content_f5_11_5300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Irritant contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Localized erythema due to irritation from benzoyl peroxide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5300=[""].join("\n");
var outline_f5_11_5300=null;
var title_f5_11_5301="Danazol: Pediatric drug information";
var content_f5_11_5301=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Danazol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"    see \"Danazol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/54/32613?source=see_link\">",
"    see \"Danazol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclomen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Androgen",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"      see \"Danazol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents and Adults: Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Begin treatment during menstruation or obtain appropriate tests to ensure patient is not pregnant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endometriosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild case: 100-200 mg twice daily for 3-6 months; may be continued up to 9 months if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate to severe case: 400 mg twice daily for 3-6 months; may be continued up to 9 months if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A gradual downward titration to a dose sufficient to maintain amenorrhea may be considered depending upon the patient's response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fibrocystic breast disease: 50-200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hereditary angioedema: Initial: 200 mg 2-3 times/day depending upon the patient's response; after a favorable response is obtained, decrease the dosage by 50% or less at intervals of 1-3 months or longer. If an attack occurs, the daily dosage may be increased by up to 200 mg.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 50 mg, 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Avoid administration with fatty meals.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of endometriosis amenable to hormonal management; fibrocystic breast disease; hereditary angioedema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Danazol may be confused with Dantrium&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F156683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Benign intracranial hypertension (rare), edema, flushing, hypertension, MI, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety (rare), chills (rare), convulsions (rare), depression, dizziness, emotional lability, fainting, fatigue, fever (rare), Guillain-Barr&eacute; syndrome (rare), headache, nervousness, sleep disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, erythema multiforme (rare), mild hirsutism, maculopapular rash, papular rash, petechial rash, pruritus, purpuric rash, seborrhea, Stevens-Johnson syndrome (rare), photosensitivity (rare), urticaria, vesicular rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea (which may continue post therapy), breast size reduction, clitoris hypertrophy (rare), glucose intolerance/glucagon changes, HDL decreased, LDL increased, libido changes, nipple discharge (rare), menstrual disturbances (spotting, altered timing of cycle), semen abnormalities (changes in volume, viscosity, sperm count/motility), sex hormone-binding globulin changes, spermatogenesis reduction, thyroid binding globulin changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite changes (rare), bleeding gums (rare), constipation, gastroenteritis, nausea, pancreatitis (rare), splenic peliosis (rare), vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginal dryness, vaginal irritation, pelvic pain (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, erythrocytosis (reversible), leukocytosis, leukopenia, platelet count increased, polycythemia, RBC increased, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic adenoma, jaundice, liver enzymes increased, malignant tumors (after prolonged use), peliosis hepatis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, carpal tunnel syndrome (rare), CPK changes, extremity pain, joint lockup, joint pain, joint swelling, muscle cramps, neck pain, paresthesia, spasms, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts (rare), visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Interstitial pneumonitis, nasal congestion (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, voice change (hoarseness, sore throat, instability, deepening of pitch)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to danazol or any component; pregnancy; undiagnosed abnormal genital bleeding; breast-feeding; porphyria; markedly impaired renal, hepatic, or cardiac function",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with seizure disorders, migraine headaches, or conditions influenced by edema",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of danazol in pregnancy is contraindicated",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; exposure to danazol",
"     <i>",
"      in utero",
"     </i>",
"     may result in androgenic effects on the female fetus; clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been reported; a sensitive test capable of determining early pregnancy is recommended immediately prior to initiation of therapy; nonhormonal method of contraception should be used during treatment if indicated. Thromboembolism, thrombotic, and thrombophlebitic events have been reported (including life-threatening or fatal stroke)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Long-term use has been associated with peliosis hepatis and hepatic adenoma",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; these conditions may be complicated by acute, potentially life-threatening intra-abdominal hemorrhage; monitor liver function. Danazol has been associated with benign intracranial hypertension (pseudotumor cerebri)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor for early signs and symptoms including papilledema, headache, nausea, vomiting, and visual disturbances. May increase risk of atherosclerosis and CAD due to decreased HDL and possible increase LDL. May cause nonreversible androgenic effects; patients should be watched closely for signs of androgenic effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F156674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Danazol may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Danazol may increase the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Danazol may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Danazol may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Danazol may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1057642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food delays time to peak serum level; high-fat meal increases plasma concentration",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Pregnancy should be ruled out prior to treatment",
"     </b>",
"     using a sensitive test (beta subunit test, if available). Nonhormonal contraception should be used during therapy. May cause androgenic effects to the female fetus; clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been reported. Therapy should be discontinued for 2 months prior to attempting pregnancy (Caballero, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, symptomatology and site of disease; serum glucose (if diabetic); HDL and LDL cholesterol; signs and symptoms of pseudotumor cerebri; androgenic effects",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Danazol, a synthetic steroid analog, has strong antigonadotropic properties. It inhibits the mid-cycle surge of LH and FSH from the pituitary resulting in suppression of ovarian steroidogenesis. Danazol does not have any progestational or estrogenic properties but does exhibit weak anabolic and androgenic effects. Through its inactivation of the pituitary-ovarian axis, regression and atrophy of normal and ectopic endometrial tissue occurs. Danazol decreases the rate of growth of abnormal breast tissue and reduces attacks associated with hereditary angioedema by increasing levels of C4 component of complement.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endometriosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fibrocystic breast disease:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: 4-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: Symptoms recur in 50% of patients within one year after discontinuation of treatment",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive hepatic metabolism to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/54/32613?source=see_link\">",
"      see \"Danazol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not discontinue without consulting prescriber; therapy may take up to several months for full benefit depending upon the purpose of treatment. Report any prodromal symptoms of hepatitis (fatigue, weakness, nausea, vomiting, dark urine, or yellowing of eyes); avoid becoming pregnant while taking this medicine and for several months after stopping; use an effective form of birth control. This medication may alter hypoglycemic requirements; diabetics should monitor serum glucose closely. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1057640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Danazol has seen limited use for treatment of ITP in children refractory to steroids. Ten children, 2.5-17 years of age were treated with 20-30 mg/kg/day in divided doses (maximum: 800 mg/day). Treatment was tapered off after patients responded to therapy (Weinblatt, 1988). Danazol has also been evaluated in hemophilia A in a randomized, double-blind placebo-controlled crossover trial in 19 children. Children &lt;15 years received 150 mg/day and &gt;15 years received 300 mg/day for 3 months. Factor VIII:C levels were increased (Mehta, 1992).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Mehta J, Singhal S, Kamath MV, et al, &ldquo;A Randomized Placebo-Controlled Double-Blind Study of Danazol in Hemophilia A,&rdquo;",
"      <i>",
"       Acta Haematol",
"      </i>",
"      , 1992, 88(1):14-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/11/5301/abstract-text/1414156/pubmed\" id=\"1414156\" target=\"_blank\">",
"        1414156",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinblatt ME, Kochen J, and Ortega J, &ldquo;Danazol for Children With Immune Thrombocytopenic Purpura,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1988, 142(12):1317-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/11/5301/abstract-text/3195531/pubmed\" id=\"3195531\" target=\"_blank\">",
"        3195531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13199 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-743D36F484-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5301=[""].join("\n");
var outline_f5_11_5301=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708691\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156636\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057632\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057624\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156615\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156600\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057635\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057628\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057634\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156684\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156683\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057639\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057623\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057622\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156674\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156608\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057642\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156611\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156622\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057631\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057621\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057637\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057638\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057630\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057640\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13199|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=related_link\">",
"      Danazol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/54/32613?source=related_link\">",
"      Danazol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_11_5302="Tuberculosis pleurisy II PA";
var content_f5_11_5302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleural calcifications due to chronic tuberculous pleurisy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic tuberculous pleurisy with extensive pleural calcifications and restriction of the right lung, accounting for the small right hemithorax and the cardiomediastinal shift to the right. Right-sided parenchymal lung scars and left-sided nodular calcified granulomata are also evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5302=[""].join("\n");
var outline_f5_11_5302=null;
var title_f5_11_5303="Pityrosporum folliculitis 2";
var content_f5_11_5303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityrosporum folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pinpoint&nbsp;follicular papules and pustules are characteristic of Pityrosporum folliculitis. The eruption most often involves the upper trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5303=[""].join("\n");
var outline_f5_11_5303=null;
var title_f5_11_5304="Intraventricular conduction delay tutorial";
var content_f5_11_5304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Intraventricular conduction delay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ST-T wave abnormalities secondary to intraventricular conduction disturbances (eg, left or right bundle branch block) look similar to those that occur during ischemia. The ST segments may be depressed or elevated; when there is an ST segment shift present, it is most often in a direction opposite to the polarity of the QRS complex. The T wave also has a polarity opposite to the direction of the QRS complex. Thus, there are typically ST segment depressions and T wave inversions in leads V1 to V3 with a right bundle branch block (RBBB), reflecting repolarization abnormalities of the right ventricular myocardium. Repolarization changes in the left ventricular myocardium due to a left bundle branch block (LBBB) result in downsloping ST depression and T wave inversion in leads V4 or V5 to V6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5304=[""].join("\n");
var outline_f5_11_5304=null;
var title_f5_11_5305="Treatment of myofascial pelvic pain syndrome in women";
var content_f5_11_5305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of myofascial pelvic pain syndrome in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/11/5305/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/11/5305/contributors\">",
"     Leah K Moynihan, RNC, MSN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/11/5305/contributors\">",
"     Eman Elkadry, MD, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/11/5305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/11/5305/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/11/5305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/11/5305/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/11/5305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of myofascial pelvic pain syndrome (MPPS) is multimodal and tailored to the individual patient. The general approach is to determine the trigger and then block or reduce ongoing stimuli that lead to pain. Most women will require a formalized program that includes pharmacologic treatment, physical therapy, and psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the treatment of MPPS. Few large randomized trials have evaluated therapy of this disorder. Our approach is based on data from a few small trials and observational studies, as well as clinical experience. Many of these studies evaluated treatment of nonpelvic myofascial pain, such as myofascial pain associated with the back, neck, shoulder, or jaw. A limitation of observational studies of pain treatment is that patients may improve because of a true treatment effect, or because the natural history of the disease includes improvement in symptoms over time, or because of the Hawthorne effect (ie, improvement in symptoms simply because the patient is in a clinical trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of MPPS are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40389?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7634723\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since identification and elimination of a specific trigger may not be possible, adjunctive therapies that provide symptom relief are also important in breaking the cycle of pain and urogenital dysfunction. Simple interventions such as meditation, progressive muscle relaxation, and attention to sleep hygiene can help to relieve physical and emotional tension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PELVIC FLOOR PHYSICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary treatment of MPPS involves manual myofascial release, stretching, and strengthening of affected areas via pelvic floor physical therapy (PFPT). Ideally, PFPT is performed by a physical therapist with specialized training in soft tissue manipulation and rehabilitation of the pelvis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33127?source=see_link\">",
"     \"Pelvic floor physical therapy for management of myofascial pelvic pain syndrome in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During a treatment session, the patient lies in the supine position as the physical therapist works to manually release the trigger points and the restricted movement of the connective tissues and muscles of the vagina, abdomen, hips, thighs, lower back, and, in some cases, the rectum. Some therapists use other modalities, such as dry needling, to hasten the release of painful tissue around surgical scars [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of finding an experienced pelvic floor physical therapist cannot be overemphasized. There is little benefit from physical therapy regimens that do not include internal vaginal release work in addition to external soft tissue manipulation and trigger point release. It is important that the patient not work with a physical therapist who focuses on tightening or strengthening the levator muscles (eg, Kegel exercises or electrical stimulation), as this can worsen symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we provide a list of local therapists' names, addresses, and phone numbers. We also warn patients that there may be a wait for an appointment with an experienced therapist. Treatment sessions are usually 45 to 60 minutes and are scheduled once or twice per week for 8 to 12 weeks. Improvement can be apparent after as few as six sessions.",
"   </p>",
"   <p>",
"    However, in our experience, women with chronic pain often require more than 12 weeks of treatment, sometimes up to or beyond one year. Others have also found that the duration of symptoms before treatment correlates with the time it takes for them to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/4\">",
"     4",
"    </a>",
"    ]. After treatment is completed, follow-up sessions may be needed periodically to treat flares of pain. Flares can develop as a result of stress, injury, sexual activity, or other physical activity (eg, prolonged sitting).",
"   </p>",
"   <p>",
"    If the patient has to travel a long distance to see a physical therapist, and remain overnight, setting up intensive physical therapy daily for a week (longer if needed) may be useful. If appropriate physical therapy is not available, other treatments (see below) can be tried. In addition, an initial visit with a physical therapist can be used to educate the patient and her partner about techniques that can be used at home. Although self-treatment is not feasible for women with trigger points in deeper vaginal muscles, a willing partner may be able to provide adjunctive treatment if an experienced therapist is not available locally [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We reviewed charts of 74 women referred to physical therapy with various pelvic floor symptoms to assess their perception of the efficacy and acceptability of the therapy. Two-thirds attended physical therapy for a median of 10 weeks (1 to 48 weeks), 58 percent reported that their symptoms were very much better or much better, 32 percent were better, 8 percent were unchanged, and 2 percent were a little worse. Some of these patients had only been in physical therapy for one week or had not completed a full course of treatment. All patients thought the therapy was an acceptable treatment modality, although 50 percent did find the treatment painful.",
"   </p>",
"   <p>",
"    Two small prospective, observational studies of patients with bladder symptoms and a high tone pelvic floor provided some evidence of benefit from manual myofascial physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. In each study, participants had PFPT performed once or twice per week. At the conclusion of treatment, all of the patients had improvement in symptoms of urinary frequency, urgency and pain. In 10 patients who underwent electromyography before and after the course of therapy, mean resting pelvic floor tension decreased from 9.73 to 3.61 microV (65 percent reduction) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial of men and women with chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome or interstitial",
"    <span class=\"nowrap\">",
"     cystitis/painful",
"    </span>",
"    bladder syndrome compared the benefit of global therapeutic massage to myofascial physical therapy. At the end of 10 weeks, the global assessment response rate was 57 percent in the myofascial therapy group compared to 21 percent in the global massage group [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/7\">",
"     7",
"    </a>",
"    ]. Further randomized trials are needed to establish the efficacy of this intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INJECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trigger point injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigger point injections of the pelvic floor may be useful for women who cannot tolerate physical therapy or as a short-acting treatment for pain flares. We use trigger point injections mostly to facilitate physical therapy, both enhancing response to physical therapy and often accelerating progress. Although the injections can be quite uncomfortable, pain is often completely relieved for some duration. Trigger point injections can be useful as a diagnostic tool if the patient&rsquo;s pain improves or resolves after injection. For women with chronic, severe pain, even temporary relief from pain can provide hope, better understanding, and motivation to follow through with treatment.",
"   </p>",
"   <p>",
"    If the injections are followed by physical therapy, the patient may note more soreness than when injections do not precede the therapy. This is because deeper physical therapy is possible when pain has been eliminated by the injections.",
"   </p>",
"   <p>",
"    Trigger points are located by palpating the soft tissues of the pelvic floor and gently applying pressure to areas that feel firm or taut. We do not use electromyography or ultrasound to locate trigger points, as there is no reliable evidence that this information improves the accuracy of trigger point injections. One small study used ultrasound guidance to enhance visualization of the needle and trigger point [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/8\">",
"     8",
"    </a>",
"    ]. Further studies are needed to determine if imaging or other studies provide superior accuracy to guide the use of trigger point injections. Clinically, patients are often able to indicate which areas of the muscles are most painful on palpation and are therefore requiring injection.",
"   </p>",
"   <p>",
"    We inject 1 to 3 mL doses of 0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    (maximum total volume 30 to 40 mL, depending on patient&rsquo;s weight) throughout the pelvic floor using a pudendal kit. Trigger points in the abdomen may also be injected, as needed, using a long (at least 1 inch) small gauge (27 g) needle. The injections can be given up to one hour before physical therapy. Duration of pain relief varies, with most patients having at least four hours of relief and some having relief for up to several days. Occasionally, a patient will have a flare of pain after the injections and experience no relief.",
"   </p>",
"   <p>",
"    Mixtures of a local anesthetic and a glucocorticoid have also been used for trigger point injections. In one prospective observational study, women were injected with a mixture of 10 mL of 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , 10 mL of 0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , and 1 mL (40 mg) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    , and assessed three months later; physical therapy was not part of the treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/9\">",
"     9",
"    </a>",
"    ]. After three months, 13 of 18 patients (72 percent) were improved and 6 of 18 patients (33 percent) were completely pain free. Limitations of this study include the small size, lack of randomization, and absence of a placebo group. However, the results are compelling, given the limited time required, few risks, and potential benefits of the treatment. In our practice, we do not typically inject glucocorticoids into the pelvic floor. However, we do inject a",
"    <span class=\"nowrap\">",
"     glucocorticoid/local",
"    </span>",
"    anesthetic mixture (1 to 3 cc bupivacaine 0.25 percent followed by 1 to 2 cc triamcinolone) at 5 and 7 o&rsquo;clock for treatment of entry dyspareunia and burning. Alternately, we have used the same combination periurethrally for women with urethral burning. Further studies should be performed to assess the efficacy of glucocorticoids in this setting.",
"   </p>",
"   <p>",
"    Some experts use a pudendal block (10 mL of 0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    injected 1 cm inferior to the right and left ischial spines) for temporary relief of myofascial pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/3\">",
"     3",
"    </a>",
"    ]. We do not generally use pudendal blocks since most patients get sufficient pain relief with trigger point injections, although we do also target the area of the pudendal nerve with 1 to 2 cc of Marcaine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Botulinum toxin injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin type A injections (BTX A) are an option for women who have refractory pain despite physical therapy, with or without trigger point injections. BTX A blocks the presynaptic release of acetylcholine from nerve endings at the neuromuscular junction, preventing contraction of the muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, it exerts a blocking action on the parasympathetic nervous system and may inhibit other neurotransmitters or affect transmission of afferent neuronal impulses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/11\">",
"     11",
"    </a>",
"    ]. The effect is temporary, lasting between three and six months.",
"   </p>",
"   <p>",
"    Prolonged muscle contraction, spasm, and inappropriately high muscle tone are thought to diminish blood supply and increase oxygen demand of the muscles of the pelvic floor. Ischemic muscle may secrete pain-producing substances, which further sensitize muscle nociceptors, alter receptor field properties, and convert wide-band mechanoreceptors to nociceptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. BTX can directly block cholinergic neuromuscular transmission and interrupt the cascade of events that lead to hyperalgesia and allodynia. BTX plays a direct role by blocking the alpha- and gamma-motor neurons, thereby preventing the abnormal pattern of muscle contraction (eg, spasm, dystonia) that activates muscle nociceptors and sensitizes the muscle pain system through mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pilot study of BTX A in 12 women administered a total dose of 40 units of BTX A injected at three concentrations (10",
"      <span class=\"nowrap\">",
"       IU/mL,",
"      </span>",
"      20",
"      <span class=\"nowrap\">",
"       IU/mL,",
"      </span>",
"      and 100",
"      <span class=\"nowrap\">",
"       IU/mL)",
"      </span>",
"      at four points in the pelvic floor [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/16\">",
"       16",
"      </a>",
"      ]. Visual analogue scores for dyspareunia and dysmenorrhea improved significantly at 12 weeks, while there were non-significant reductions in non-menstrual pain and dyschezia. There were no significant differences in pain scores, quality of life, or pelvic floor pressure measurements between the three dilutions of BTX A. Quality of life scores were improved at 12 weeks, although this did not reach statistical significance. There were no reports of new onset urinary or fecal incontinence.",
"     </li>",
"     <li>",
"      A second trial found that injections of a total dose of 80 units of BTX A (20",
"      <span class=\"nowrap\">",
"       IU/mL)",
"      </span>",
"      significantly reduced dysmenorrhea and dyspareunia-associated pain compared to injections of saline [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/17\">",
"       17",
"      </a>",
"      ]. BTX A reduced non-menstrual pelvic pain and dyschezia, although this did not reach statistical significance. There were no reports of new urinary or fecal incontinence or urinary retention, although two participants became pregnant; one woman delivered a healthy infant while the other woman's infant was born with a ventriculo-septal defect.",
"     </li>",
"     <li>",
"      Other small trials of BTX have reported similar improvements in pain ratings [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/18-22\">",
"       18-22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study of the risks and benefits of BTX A injections are clearly needed. However, in the absence of large, randomized, placebo controlled trials, we believe it is reasonable to consider the use of BTX A in conjunction with PFPT for women with refractory myofascial pelvic pain. We suggest botulinum toxin A injections when PFPT is not possible due to severe pain, for women with persistent pain after six to eight sessions of PFPT, for women who are not making progress with PFPT, or if there is an identifiable muscle spasm that could account for her symptoms.",
"   </p>",
"   <p>",
"    In our practice, we give 300 IU of BTX A. Each 100-unit vial is diluted in 10 mL of preservative free saline, and 1 to 2 mLs are injected into each palpable trigger point and tender area throughout the pelvic floor. Most patients tolerate the injections in the office setting, although the occasional patient requires sedation and injections in the operating room. Local application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    jelly before injection and ice packs after injection may be helpful for injection-related pain.",
"   </p>",
"   <p>",
"    Most patients begin to feel relief of pain within one to two weeks. Physical therapy and trigger point injections may be resumed one week after the BTX injections. We do not use trigger point injections concurrently with BTX A due to the theoretic risk of diluting the BTX A or not getting adequate infiltration of the most painful trigger points.",
"   </p>",
"   <p>",
"    Repeat injections of BTX are sometimes necessary, but should not be given sooner than three months after the previous BTX injection. Repeat injections of BTX are considered if the first series of injections was effective and the woman did not have significant side effects.",
"   </p>",
"   <p>",
"    We counsel patients extensively regarding risks of intrapelvic BTX injections, including risk of incontinence, weakness, and the rare, but serious, risk of systemic complications. A few patients in our practice have developed short-term complications related to these injections, such as transient flu-like symptoms, severe constipation, urinary retention, and fecal incontinence. Others have developed bothersome vaginal or rectal pressure, despite resolution of vaginal pain. All of these side effects gradually resolved within about three months as the effects of BTX wore off.",
"   </p>",
"   <p>",
"    One potential limitation of BTX treatment is its cost. Some commercial insurers in the United States do not cover the cost of the BTX for treatment of MPPS, and the cost of self-payment ($450 to $700 per vial, with up to three vials needed) is prohibitive in many cases. In these cases, we recommend communicating with the insurer&rsquo;s medical director to advocate for the use of BTX given the low risk, potential benefits, and limited alternatives to intrapelvic BTX, especially in those women who have tried multiple other treatments without success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture may play a role in management of musculoskeletal pain. A detailed overview of this technique can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"     \"Acupuncture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review evaluated 134 studies of acupuncture or dry needling (no anesthetic injection) for management of myofascial trigger point pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/23\">",
"     23",
"    </a>",
"    ]. The review included studies in which one group was treated by needling directly into the myofascial trigger points, while a control group received no treatment, usual care, indirect local dry needling, or a placebo intervention. There was a trend toward treatment efficacy, but major differences in study design, quality, and size limited the ability to analyze combined data. More and better trials are needed.",
"   </p>",
"   <p>",
"    While we do not routinely refer patients for acupuncture treatment, we do not discourage it, especially if other treatment modalities have not been helpful and the patient is interested in trying it. Our limited experience with acupuncture is that it can help to improve coping and decrease pain perception, at least temporarily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DRUG TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDS) are often used in the treatment of chronic pelvic pain. We suggest a trial of these drugs as first-line therapy in women with",
"    <strong>",
"     mild",
"    </strong>",
"    symptoms; however, we have found NSAIDs are of limited to no benefit in patients with moderate to severe pain, and NSAIDs are usually not helpful during flares. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NSAIDs should be discontinued at least three days prior to trigger point or BTX A injections to minimize the risk of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    is useful for treatment of neuropathic pain. Given that there is evidence for a neurogenic etiology of myofascial pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], this drug is our first-line choice for women with moderate to severe pelvic or vaginal pain that is chronic and is interfering with sleep or the ability to perform normal daily activities. We initiate therapy with gabapentin 100 mg at bedtime, and increase the dose by 100 mg per week to 300 mg three times per day. The dose may be increased further, depending upon the patient's symptoms and ability to tolerate side effects. The maximum tolerated dose in long-term clinical trials is 2400 mg per day in divided doses. It may take four to six weeks to observe an effect. The dose must be tapered over at least one week before it is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pregabalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is also useful for treatment of neuropathic pain. In some patients, it is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ; however, side effects such as forgetfulness, drowsiness, weight gain, and feeling foggy, loopy, or euphoric limit its use. Pregabalin can be given less frequently (twice daily) than gabapentin (usually three times daily), but side effects can be more troublesome and it has a small potential for abuse (schedule V drug).",
"   </p>",
"   <p>",
"    Due to potentially bothersome side effects, we initiate treatment with a small dose, 25 mg at bedtime, and then slowly increase to 75 mg twice daily. Higher doses (up to 600 mg per day) can be used if the medication is well-tolerated. We initiate treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    if moderate to high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    do not improve symptoms of pain. It may take four to six weeks to observe an effect. The dose should be tapered before it is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19238359\">",
"    <span class=\"h2\">",
"     Serotonin-norepinephrine reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serotonin-norepinephrine reuptake inhibitors (SNRIs), including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    , are indicated for treatment of fibromyalgia and may be useful off label for women with MPPS. There are no data on the use of SNRIs for the treatment of myofascial pain. Side effects, such as nausea and vomiting, can be a limiting factor. Starting with a low dose and titrating up slowly can help to improve tolerability.",
"   </p>",
"   <p>",
"    In our practice, we find that a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , along with an SNRI, is useful to address the centralized nature of neuropathic pain. We offer this combination to women who have moderate to severe pain that affects activities of daily living and who have failed treatment with gabapentin or pregabalin alone. Consultation with a neurologist, physiatrist, or pain specialist can be helpful for healthcare providers who are uncomfortable or unfamiliar with these medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pentosan polysulfate sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=see_link\">",
"     Pentosan polysulfate sodium",
"    </a>",
"    is a common oral treatment for painful bladder",
"    <span class=\"nowrap\">",
"     syndrome/interstitial",
"    </span>",
"    cystitis and may be helpful when bladder pain occurs in the setting of myofascial pain. Relief of symptoms takes three to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The manufacturer recommends a dose of 100 mg three times daily, although we often counsel patients to take 200 mg two times per day to improve compliance.",
"   </p>",
"   <p>",
"    We offer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=see_link\">",
"     pentosan polysulfate sodium",
"    </a>",
"    for women who have painful bladder symptoms as a major component of MPPS and who cannot or will not undergo PFPT.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=see_link\">",
"     Pentosan polysulfate",
"    </a>",
"    sodium could be considered as a second-line therapy for women with painful bladder symptoms who are refractory to PFPT. However, studies of pentosan polysulfate sodium show only a moderate benefit and the benefit of treatment may not be seen for up to three months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricyclic antidepressants (TCAs) are commonly prescribed (unlabeled use) for treatment of a variety of chronic pain states, with or without coexisting depression. However, there are few data on the use of TCAs for treatment of myofascial pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Bothersome side effects (eg, anticholinergic effects, moderate to marked sedation) are a limiting factor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When we use a TCA, we generally prescribe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , starting at the lowest dose (10 mg) at bedtime. The dose can be increased weekly to as much as 50 to 100 mg until an acceptable balance between pain relief and side effects is achieved. Other tricyclic antidepressants are probably equally effective, and may have a different side effect profile. We generally reserve use of TCAs for women with chronic, moderate to severe pelvic pain who cannot afford or tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;These drugs have both muscle relaxant and anxiolytic effects, and are used to treat chronic pain; however, there is much less experience in their use for treatment of myofascial pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We have successfully used both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    to reduce pain during a flare and to improve sleep disturbance due to pain and urinary urgency. We typically prescribe diazepam (2 to 5 mg at bedtime, or up to three times per day as needed). We strongly caution patients to avoid over-use because of the potential for dependency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19238418\">",
"    <span class=\"h2\">",
"     Vaginal treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal administration of a benzodiazepine, such as valium, sometimes in combination with a local anesthetic and muscle relaxant, can help to reduce pain and muscle spasm. Two small retrospective studies showed improvement in pain scores after treatment with 5 to 10 mg vaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In our practice, we typically start with 10 mg diazepam, and add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    2 percent or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    10 mg as needed for pain or spasm. We use a compounding pharmacy to suspend the diazepam in silica gel and a fatty acid that melts at body temperature. While whole or crushed diazepam tablets can be inserted directly into the vagina, we do not recommend this due to variable absorption and to decreased risk of oral use and subsequent dependancy. The treatment is minimally absorbed into the bloodstream [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/30\">",
"     30",
"    </a>",
"    ] and can be used up to three times daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    helpful in alleviating pain in a subgroup of patients with severe myofascial pain and hypertonic pelvic floor. Baclofen is an anti-spasmodic that has been used to treat chronic pain syndromes, but there are no published reports of treatment of myofascial pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"     \"Overview of polyneuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We start with 5 mg daily and increase by 5",
"    <span class=\"nowrap\">",
"     mg/dose",
"    </span>",
"    every three days to a maximum dose of 10 mg three times per day. Abrupt withdrawal should be avoided because severe sequelae have been reported. For this reason, we only prescribe this drug after obtaining clearance from the patient's primary care provider and with ongoing follow-up by this provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19238437\">",
"    <span class=\"h2\">",
"     Skeletal muscle relaxants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     Cyclobenzaprine",
"    </a>",
"    is a centrally-acting skeletal muscle relaxant that can be useful in relieving pain caused by muscle spasm. There are multiple studies showing a benefit of cyclobenzaprine in the treatment of fibromyalgia or muscle spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/31\">",
"     31",
"    </a>",
"    ], but few studies have specifically examined the effect of cyclobenzaprine in myofascial pain. We have used cyclobenzaprine for women with MPPS, usually in combination with other treatments. We typically start at 5 mg at bedtime, and increase to 10 mg as tolerated. Most women experience sleepiness with cyclobenzaprine, limiting its use to bedtime.",
"   </p>",
"   <p>",
"    Other skeletal muscle relaxants, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/methocarbamol-drug-information?source=see_link\">",
"     methocarbamol",
"    </a>",
"    , and",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/carisoprodol-drug-information?source=see_link\">",
"     carisoprodol",
"    </a>",
"    , are available and are probably as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    . We tend to avoid tizanidine due to the potential for drug interactions with other commonly used medications (including fluoroquinolones and oral contraceptives).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Narcotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the addictive potential of narcotics and lack of long-term benefit, we rarely prescribe narcotics. If a patient is already taking narcotics for MPPS or has not responded to other therapies, we manage the patient concurrently with a pain center or a clinician experienced in monitoring long-term use of narcotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vaginal estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophic vaginitis can trigger or exacerbate myofascial pain in some women. Estrogen can ameliorate vaginal irritation due to atrophic changes and may reduce vaginal pain and irritative voiding symptoms.",
"   </p>",
"   <p>",
"    We suggest vaginal suppositories, which are well tolerated and have minimal systemic effects. Some patients find estrogen creams to be irritating, possibly due to the inflammatory changes associated with MPPS. A 10 mcg tablet of estradiol for vaginal use is effective for relief of vaginal symptoms, and is inserted into the vagina daily for two weeks and then twice per week thereafter. We occasionally recommend increasing the dose to three times per week if insufficient effects are seen. Estradiol levels in plasma minimally increase during use of these tablets, although not to premenopausal levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergics can help relieve urinary urgency, frequency, and urge incontinence; however, they often provide incomplete relief in women with myofascial pain. They can be used in women with severe irritative voiding problems to provide some symptom control prior to a course of physical therapy. In our experience, once patients have started to respond to PFPT, they no longer require these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of urinary incontinence\", section on 'Antimuscarinics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19238445\">",
"    <span class=\"h2\">",
"     Eye movement desensitization and reprocessing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eye movement desensitization and reprocessing (EMDR) is a psychotherapy technique that was initially developed to treat people with posttraumatic stress disorder. Over time, it has been used to treat people with other trauma-related conditions, including chronic pain. The goal of EMDR is to guide patients to process memories or experiences that are contributing to pain and to use these past experiences to create positive experiences in the future. EMDR is conducted one-on-one by a therapist who has specific training in the process. A full description of the EMDR method is available at www.emdrnetwork.org.",
"   </p>",
"   <p>",
"    Clinical studies of EMDR in women with MPPS are lacking. However, there are a number of studies supporting the benefit of EMDR for people with a history of sexual or other emotional trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In our practice, we have used EMDR in women with MPPS who have a history of trauma, as well as in women who have a long history of chronic pain in whom other treatments have not provided significant relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19238460\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    patch to placebo patch and trigger point injection with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/34\">",
"     34",
"    </a>",
"    ]. Both lidocaine patch and trigger point injections were effective in reducing pain compared to placebo. In our practice, we occasionally use lidocaine patches for women who have pain that is localized to areas on the abdomen, low back, or hips. The woman can use up to three patches at a time for up to 12 hours per 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SACRAL NEUROMODULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sacral neuromodulation appears to provide some relief for some women who have refractory painful bladder",
"    <span class=\"nowrap\">",
"     syndrome/interstitial",
"    </span>",
"    cystitis, although there are few studies of the use of neuromodulation for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our experience, neuromodulation for urinary urgency and frequency in the setting of myofascial pain is sometimes effective to relieve pain. Initially, there may be a marked improvement of pain; however, there is often a gradual increase in pain and habituation to the stimulation, despite reprogramming. Therefore, we do not usually recommend sacral neuromodulation as an initial or long-term treatment of MPPS. Future trials are needed to determine the role of neuromodulation for myofascial pelvic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT OF FLARES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bladder instillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If painful or irritative voiding symptoms are manifested during a flare of myofascial pelvic pain syndrome (MPPS), a bladder instillation of a local anesthetic and other medications can be helpful can be helpful in providing short-term relief. A solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    can be helpful in providing short-term relief. In our practice, occasionally we also add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    in an effort to decrease burning and inflammation. &nbsp;Instillations are often done in the office, although patients can learn to administer the solution at home through self-catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link&amp;anchor=H284183#H284183\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\", section on 'Intravesical lidocaine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Urinary analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary analgesics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/7/41075?source=see_link\">",
"     phenazopyridine",
"    </a>",
"    , can provide temporary relief of dysuria and urgency. However, long-term use is not recommended due to the risk of hepatotoxicity. The possibility of urinary tract infection should be excluded by culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link&amp;anchor=H899949177#H899949177\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ice, heat, stretch/massage, exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of conservative treatments, such as ice, heat, stretching, self-massage, and exercise, can sometimes help to temporarily relieve the discomfort associated with MPPS. Stress management is also an important part of the treatment plan, as chronic daily or intermittent stress can exacerbate muscle tension.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Stretch/massage",
"      </span>",
"      &mdash; Patients with accessible trigger points can treat themselves. We instruct our patients to massage, skin roll, and perform scar release in painful areas. Some patients find this more useful than rest, ice, heat and exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin rolling is performed by applying a light moisturizing cream or lotion and using both hands to gently grasp sections of skin in the affected area (eg, abdomen, inner or outer thigh). The skin is rolled gently between the fingers, with the goal being to release restrictions in the underlying connective tissue. A sharp pinching sensation and erythema are common reactions, especially early in treatment.",
"   </p>",
"   <p>",
"    Scar release is performed similarly, with the fingers grasping the tissue on either side of the scar. The scar should be gently pulled away from the body and rolled between the fingers. The tissue can also be lightly and deeply massaged.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ice &mdash; Most of our patients find that application of ice to painful areas of the abdomen or perineum provides short-term relief of pain, especially during a flare or after sexual intercourse. Ice can be placed intravaginally by filling a finger of a non-sterile examination glove or a condom and inserting into the vagina. We generally recommend applying ice for no more than 20 minutes.",
"     </li>",
"     <li>",
"      Heat &mdash; For women who cannot tolerate ice, heat can also be soothing during a flare. A hot water bottle or heating pad may be used, although care must be taken to avoid burns.",
"     </li>",
"     <li>",
"      Exercise &mdash; Women appear to view exercise as more effective for decreasing muscle pain than men [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/35\">",
"       35",
"      </a>",
"      ]. There is no single exercise proven to reduce pain or tightness related to MPPS. We suggest regimens that include stretching and strengthening (eg, yoga, pilates).",
"     </li>",
"     <li>",
"      Stress management &mdash; Anxiety predisposes some women to continuously contract their muscles, including those of the pelvic floor. Depression and anxiety often coexist with chronic pain and may exacerbate pain [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/36\">",
"       36",
"      </a>",
"      ]. This association has even been noted in adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/37\">",
"       37",
"      </a>",
"      ]. In our experience, uncontrolled anxiety and pain are associated with poorer outcomes and the need for a longer treatment course. Treatment must take depression and anxiety into account. It is important to include a multidisciplinary approach in these women, with the use of psychotherapy or psychopharmacology as needed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5305/abstract/38\">",
"       38",
"      </a>",
"      ]. Use of stress reduction techniques such as deep breathing, visualization, meditation, progressive muscle relaxation, or prayer are suggested, as well.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of myofascial pelvic pain syndrome (MPPS) is multimodal and tailored to the individual patient. The general approach is to determine the trigger and then block or reduce ongoing stimuli that lead to pain. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with mild pain and flares, we suggest simple interventions rather than invasive therapy or prescription drugs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These interventions include meditation, relaxation exercises,",
"      <span class=\"nowrap\">",
"       stretch/massage,",
"      </span>",
"      heat, ice, or nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment of flares'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with moderate to severe myofascial pelvic pain, we suggest pelvic floor physical therapy as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pelvic floor physical therapy'",
"      </a>",
"      above.) Improvement occurs within three to six weeks. Trigger point injections of the pelvic floor may be useful for women who cannot tolerate physical therapy or as a short-acting treatment for pain flares. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Trigger point injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with moderate to severe myofascial pelvic pain that is interfering with their usual activities, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      as first-line pharmacologic therapy (in addition to pelvic floor physical therapy) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Gabapentin'",
"      </a>",
"      above.) If this is ineffective after six weeks, we suggest stopping gabapentin and starting a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregabalin'",
"      </a>",
"      above.) These drugs must be tapered over at least one week before being discontinued.",
"     </li>",
"     <li>",
"      We suggest botulinum toxin A injections when physical therapy is not possible due to severe pain, for women with persistent pain after six to eight sessions of physical therapy, for women who are not making progress with physical therapy, or if there is an identifiable muscle spasm that could account for her symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Botulinum toxin injections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/1\">",
"      Yap EC. Myofascial pain--an overview. Ann Acad Med Singapore 2007; 36:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/2\">",
"      Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. JAMA 1994; 271:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/3\">",
"      FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. II: Treatment of the patient with the short pelvic floor. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/4\">",
"      Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol 2001; 166:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/5\">",
"      Fisher KA. Management of dyspareunia and associated levator ani muscle overactivity. Phys Ther 2007; 87:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/6\">",
"      Oyama IA, Rejba A, Lukban JC, et al. Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. Urology 2004; 64:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/7\">",
"      FitzGerald MP, Anderson RU, Potts J, et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009; 182:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/8\">",
"      Niraj G, Collett BJ, Bone M. Ultrasound-guided trigger point injection: first description of changes visible on ultrasound scanning in the muscle containing the trigger point. Br J Anaesth 2011; 107:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/9\">",
"      Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn 2007; 26:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/10\">",
"      Volknandt W. The synaptic vesicle and its targets. Neuroscience 1995; 64:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/11\">",
"      Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the \"sausage poison\". Neurology 1999; 53:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/12\">",
"      Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain 2001; 17:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/13\">",
"      Issberner U, Reeh PW, Steen KH. Pain due to tissue acidosis: a mechanism for inflammatory and ischemic myalgia? Neurosci Lett 1996; 208:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/14\">",
"      Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil 1998; 79:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/15\">",
"      Knutson GA. The role of the gamma-motor system in increasing muscle tone and muscle pain syndromes: a review of the Johansson/Sojka hypothesis. J Manipulative Physiol Ther 2000; 23:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/16\">",
"      Jarvis SK, Abbott JA, Lenart MB, et al. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 2004; 44:46.",
"     </a>",
"    </li>",
"    <li>",
"     Abbott, JA, Jarvis, SK, Lyons, SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women. Obstet Gynecol 2006:108:915.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/18\">",
"      Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res 2007; 19:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/19\">",
"      Dykstra DD, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med 2006; 51:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/20\">",
"      Thomson AJ, Jarvis SK, Lenart M, et al. The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG 2005; 112:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/21\">",
"      Romito S, Bottanelli M, Pellegrini M, et al. Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest 2004; 58:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/22\">",
"      Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004; 104:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/23\">",
"      Tough EA, White AR, Cummings TM, et al. Acupuncture and dry needling in the management of myofascial trigger point pain: a systematic review and meta-analysis of randomised controlled trials. Eur J Pain 2009; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/24\">",
"      FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. I: Background and patient evaluation. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/25\">",
"      FitzGerald MP, Brensinger C, Brubaker L, et al. What is the pain of interstitial cystitis like? Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/26\">",
"      Shah JP, Danoff JV, Desai MJ, et al. Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points. Arch Phys Med Rehabil 2008; 89:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/27\">",
"      Manfredini D, Landi N, Tognini F, et al. Muscle relaxants in the treatment of myofascial face pain. A literature review. Minerva Stomatol 2004; 53:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/28\">",
"      Melis M, Secci S. Diagnosis and treatment of atypical odontalgia: a review of the literature and two case reports. J Contemp Dent Pract 2007; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/29\">",
"      Rogalski MJ, Kellogg-Spadt S, Hoffmann AR, et al. Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction. Int Urogynecol J 2010; 21:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/30\">",
"      Carrico DJ, Peters KM. Vaginal diazepam use with urogenital pain/pelvic floor dysfunction: serum diazepam levels and efficacy data. Urol Nurs 2011; 31:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/31\">",
"      Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum 2004; 51:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/32\">",
"      Vickerman KA, Margolin G. Rape treatment outcome research: empirical findings and state of the literature. Clin Psychol Rev 2009; 29:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/33\">",
"      Posmontier B, Dovydaitis T, Lipman K. Sexual violence: psychiatric healing with eye movement reprocessing and desensitization. Health Care Women Int 2010; 31:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/34\">",
"      Affaitati G, Fabrizio A, Savini A, et al. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 2009; 31:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/35\">",
"      Dannecker EA, Knoll V, Robinson ME. Sex differences in muscle pain: self-care behaviors and effects on daily activities. J Pain 2008; 9:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/36\">",
"      Roth RS, Punch MR, Bachman JE. Patient beliefs about pain diagnosis in chronic pelvic pain: relation to pain experience, mood and disability. J Reprod Med 2011; 56:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/37\">",
"      Hoftun GB, Romundstad PR, Rygg M. Factors associated with adolescent chronic non-specific pain, chronic multisite pain, and chronic pain with high disability: the Young-HUNT Study 2008. J Pain 2012; 13:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5305/abstract/38\">",
"      Meltzer-Brody S, Leserman J. Psychiatric Comorbidity in Women with Chronic Pelvic Pain. CNS Spectr 2011.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5429 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5305=[""].join("\n");
var outline_f5_11_5305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7634723\">",
"      ADJUNCTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PELVIC FLOOR PHYSICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INJECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trigger point injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Botulinum toxin injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DRUG TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pregabalin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19238359\">",
"      Serotonin-norepinephrine reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pentosan polysulfate sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19238418\">",
"      Vaginal treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Baclofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19238437\">",
"      Skeletal muscle relaxants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Narcotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vaginal estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19238445\">",
"      Eye movement desensitization and reprocessing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19238460\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SACRAL NEUROMODULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT OF FLARES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bladder instillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Urinary analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ice, heat, stretch/massage, exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40389?source=related_link\">",
"      Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=related_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=related_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33127?source=related_link\">",
"      Pelvic floor physical therapy for management of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_11_5306="Twin pregnancy: Labor and delivery";
var content_f5_11_5306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Twin pregnancy: Labor and delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/11/5306/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/11/5306/contributors\">",
"     Stephen T Chasen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/11/5306/contributors\">",
"     Frank A Chervenak, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/11/5306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/11/5306/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/11/5306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/11/5306/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/11/5306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twin pregnancies are at increased risk of intrapartum complications, such as fetal heart rate abnormalities and complications related to malpresentation. This topic will review issues related to the delivery of twins, such as timing and route of delivery, fetal monitoring, maternal",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia,",
"    </span>",
"    and management of delivery. Antepartum assessment and neonatal management of these pregnancies, and monoamniotic twin pregnancy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link\">",
"     \"Twin pregnancy: Prenatal issues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43511?source=see_link\">",
"     \"Monoamniotic twin pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=see_link\">",
"     \"Neonatal outcome, complications, and management of multiple births\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous or medically indicated preterm birth complicates over 50 percent of twin pregnancies, thus scheduling the timing of delivery is not subject to the discretion of the obstetrician in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in the absence of a spontaneous or medically indicated preterm delivery, when should ongoing twin pregnancies be delivered?",
"   </p>",
"   <p>",
"    In general, we agree with expert consensus guidelines for timing of delivery of twin gestations. A consensus opinion from a workshop held by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Society for Maternal-Fetal Medicine (SMFM) suggested delivery at 38 weeks for uncomplicated dichorionic twins and 34 to 37 weeks for uncomplicated monochorionic diamniotic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/2\">",
"     2",
"    </a>",
"    ]. The National Institute for Health and Clinical Excellence (NICE) recommends elective delivery of dichorionic twin pregnancies from 37 weeks of gestation and monochorionic twin pregnancies from 36 weeks (after a course of corticosteroids) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/3\">",
"     3",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists (ACOG) recommends delivery of uncomplicated dichorionic twins at",
"    <span class=\"nowrap\">",
"     38",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     38",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks and uncomplicated monochorionic twins at",
"    <span class=\"nowrap\">",
"     34",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     37",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/4\">",
"     4",
"    </a>",
"    ]. Twin pregnancies complicated by fetal growth restriction are delivered earlier, with timing depending on the clinical scenario.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dichorionic/diamniotic twin pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For normal uncomplicated",
"    <span class=\"nowrap\">",
"     dichorionic/diamniotic",
"    </span>",
"    twin pregnancies, we suggest elective delivery between 38 and 40 weeks of gestation.",
"   </p>",
"   <p>",
"    There are no high quality data from randomized trials on which to base a recommendation for the optimum timing of delivery of",
"    <span class=\"nowrap\">",
"     dichorionic/diamniotic",
"    </span>",
"    twins. Based on our experience and the data presented below, we avoid elective delivery (ie, in the absence of usual maternal or fetal indications for delivery) of",
"    <span class=\"nowrap\">",
"     dichorionic/diamniotic",
"    </span>",
"    twins prior to 38 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Assessment of fetal lung maturity should be performed if elective delivery is considered prior to 38 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the presence of complications associated with increased perinatal mortality, such as oligohydramnios, abnormal fetal growth, or maternal hypertension, delivery prior to 38 weeks without confirmation of lung maturity is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Optimal length of gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal length of gestation may be shorter in twin than in singleton pregnancies. Epidemiological evidence shows that the lowest rate of perinatal mortality (PNM) occurs at an earlier gestational age and at lower birth weight in twins than in singletons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. This was illustrated in two large analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study comparing PNM among 89,000 infants born of multifetal pregnancies to PNM in six million singleton infants reported that PNM in twin gestations reached a nadir at 37 to 38 weeks of gestation and then increased, while the lowest PNM in singleton pregnancies was at 39 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from the United States National Center for Health Statistics, including over 11 million singleton and almost 300,000 twin births, showed that the lowest PNM for singletons was at 39 to 41 weeks (approximately 1 fetal and 1 neonatal death per 1000 deliveries), but for twins lowest PNM was at 37 to 39 weeks (3 to 4 fetal and 2 neonatal deaths per 1000 deliveries) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/12\">",
"       12",
"      </a>",
"      ]. Moreover, as of 39 weeks gestation, the prospective risk of fetal death in an ongoing twin pregnancy exceeded the risk of neonatal death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional smaller series have confirmed these findings. However, the only two randomized trials that tried to determine whether delivery at 37 weeks resulted in better outcomes than later delivery had too few patients (n = 36, n = 235) to detect significant differences [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When all twin pregnancies are considered, the lowest perinatal mortality for twin pregnancy appears to be at 37 to 38 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/10,12,15-22\">",
"     10,12,15-22",
"    </a>",
"    ] and delivery before 38 weeks is associated with higher neonatal morbidity than later delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/18,23,24\">",
"     18,23,24",
"    </a>",
"    ]. However, when only uncomplicated dichorionic twin gestations are considered,",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    falls through 39 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/7\">",
"     7",
"    </a>",
"    ]. Therefore, in uncomplicated pregnancies and when the twins are continuing to grow and mature, we and others feel it is reasonable to deliver at or after 38 completed weeks of gestation to minimize the frequency of neonatal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/7,23-26\">",
"     7,23-26",
"    </a>",
"    ]. However, there is no consensus on the optimum time to deliver these pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Assessment of pulmonary maturity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is widespread belief that fetuses of twin gestations experience more rapid pulmonary maturation than singleton fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/27\">",
"     27",
"    </a>",
"    ], this assertion has been challenged by conflicting data [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The potential for neonatal respiratory problems is particularly important when considering the optimal timing of delivery of twins since many of these pregnancies are delivered by cesarean birth prior to the onset of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with singletons, there appears to be a significant risk of respiratory problems in late preterm twins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated the prevalence of neonatal respiratory disorders in the infants of 126 women with twins who underwent elective cesarean delivery before labor (at 36 to 40 weeks of gestation) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/5\">",
"       5",
"      </a>",
"      ]. The majority (65 percent) of cesarean deliveries were performed due to malpresentation in one or both fetuses; there were no maternal or fetal complications (eg, severe preeclampsia, fetal growth restriction) requiring medically indicated delivery. Neonatal respiratory disorders occurred frequently, and more often among infants born at 36 to 37 compared to 38 or more weeks of gestation (13 versus 2 percent).",
"     </li>",
"     <li>",
"      In another series of twins delivered by the vaginal or abdominal route, the prevalence of respiratory morbidity at 36 to 37 weeks was 23 percent, compared to 7 percent at 37 to 38 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, fetal pulmonary maturity should be evaluated if elective early delivery is planned. Some authors, including ourselves, feel that amniocentesis of only one twin is adequate if the gestation is &ge;36 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/27,34\">",
"     27,34",
"    </a>",
"    ], but others test both twins in all cases because pulmonary maturity can be asynchronous [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on review of these data [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/5,34,35\">",
"     5,34,35",
"    </a>",
"    ], the American College of Obstetricians and Gynecologists suggested amniocentesis before elective delivery of twins less than 38 and",
"    <span class=\"nowrap\">",
"     0/7ths",
"    </span>",
"    weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/8\">",
"     8",
"    </a>",
"    ]. They state that amniocentesis of only one twin is generally sufficient at a gestational age",
"    <span class=\"nowrap\">",
"     &ge;33",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks since discordancy is uncommon at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], but they suggest amniocentesis of both twins when the procedure is performed earlier in pregnancy. When only one sac is sampled, it would be reasonable to sample the sac of the fetus less likely to be mature. As an example, a non-presenting, larger, male fetus would be less likely to have achieved lung maturity than a smaller, presenting female fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=see_link\">",
"     \"Assessment of fetal lung maturity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Upper gestational age limit",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the rare twin pregnancy in which labor has not occurred by 40 weeks of gestation and no fetal or maternal indications for delivery are present, we electively intervene to deliver the twins. There are few studies evaluating the upper gestational age limit for allowing a twin pregnancy to remain undelivered. One such series included over 60,000 twin pairs delivered at 37 or more weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/26\">",
"     26",
"    </a>",
"    ]. The odds of neonatal death (unrelated to congenital anomalies) significantly increased at &ge;40 weeks compared with 37 weeks of gestation (OR 4.24, 95% CI 2.65-7.00). NICE guidelines state continuing uncomplicated twin pregnancies beyond 38 weeks 0 days increases the risk of fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monochorionic/diamniotic twin pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that have evaluated the optimum time for delivery of",
"    <span class=\"nowrap\">",
"     monochorionic/diamniotic",
"    </span>",
"    twin gestations. Based on the higher risk of intrauterine mortality in these pregnancies, some experts have argued for delivery as early as 32 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/2,36-39\">",
"     2,36-39",
"    </a>",
"    ]. While it is not clear that elective delivery prior to 37 weeks of gestation is warranted in apparently uncomplicated",
"    <span class=\"nowrap\">",
"     monochorionic/diamniotic",
"    </span>",
"    twin pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/40\">",
"     40",
"    </a>",
"    ], it is our practice, and that of other experts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/2,4,7,41,42\">",
"     2,4,7,41,42",
"    </a>",
"    ], to discuss this risk and offer delivery of",
"    <span class=\"nowrap\">",
"     monochorionic/diamniotic",
"    </span>",
"    twins at 36 to 37 weeks of gestation. Delivery at about this time provides a reasonable trade-off between the morbidity of preterm birth, which falls with advancing gestation age, and the risk of unanticipated subsequent fetal demise. In one study, the perinatal morbidity rate and the prospective risk of fetal death at 36 to 37 weeks were 9 and 1 percent, respectively, in closely monitored pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/7\">",
"     7",
"    </a>",
"    ]. We do not perform amniocentesis to document lung maturity prior to delivery at 36 to 37 weeks in",
"    <span class=\"nowrap\">",
"     monochorionic/diamniotic",
"    </span>",
"    twins.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Monochorionic/diamniotic",
"    </span>",
"    twin pregnancies with twin-twin transfusion syndrome are delivered earlier. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9913?source=see_link\">",
"     \"Management of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Monoamniotic twin pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional issues must be addressed in timing the delivery of a monoamniotic twin pregnancy. Delivery earlier in the third trimester may be indicated because of the high rate of perinatal mortality described in these pregnancies despite intensive fetal surveillance, (30 to 70 percent, which is likely due to cord entanglement) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Management of monoamniotic twin pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43511?source=see_link\">",
"     \"Monoamniotic twin pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ROUTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether route of delivery affects morbidity and mortality is controversial. The presentation and, in some situations, the gestational age of twins can influence the selection of vaginal versus cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Should routine cesarean delivery be offered?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery is common in twin pregnancies: over 60 percent of twin births are by cesarean [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/45\">",
"     45",
"    </a>",
"    ]. Some investigators have proposed that neonatal outcome could be improved by a policy of routine cesarean delivery for all twin pregnancies. The basis for this proposal is concern that the relative risk of anoxic death of the second twin is increased as a result of mechanical problems (eg, compound presentation, cord prolapse, abruptio placentae) after vaginal birth of the first twin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/46\">",
"     46",
"    </a>",
"    ]; this is most significant in gestations &ge;36 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/47\">",
"     47",
"    </a>",
"    ]. However, others have pointed out that even though the relative risk of neonatal mortality may be increased, the absolute risk remains low and, therefore, a large number of cesareans would have to be done to prevent one death of a second twin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/48\">",
"     48",
"    </a>",
"    ]. Cesarean delivery also poses risks to the mother. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=see_link&amp;anchor=H3#H3\">",
"     \"Cesarean delivery: Postoperative issues\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=see_link&amp;anchor=H17#H17\">",
"     \"Cesarean delivery: Postoperative issues\", section on 'Long-term risks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not believe that there is adequate evidence to support a policy of routine cesarean delivery of twin pregnancies, although data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The best evidence comes from a systematic review of four studies including almost 1000 twin pregnancies (one randomized trial and three cohort studies published before 2001) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/49\">",
"       49",
"      </a>",
"      ]. This analysis did not find a statistically significant difference in perinatal or neonatal mortality for twins delivered after planned cesarean delivery compared to those delivered after a trial of labor (planned vaginal delivery) (odds of death after planned cesarean 2.06, 95% CI 0.29-14.66 trend favors vaginal delivery). Planned cesarean delivery was also associated with a higher rate of neonatal respiratory problems, such as transient tachypnea. Given the wide confidence interval, this analysis is clearly inadequate for conclusively determining which route of delivery should be offered.",
"     </li>",
"     <li>",
"      A subsequent systematic review of four studies published from 2005 to 2010 also found that planned vaginal delivery (n = 905) resulted in neonatal morbidity and mortality rates for second twins that were statistically similar to those for planned cesarean delivery (n = 297) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/50\">",
"       50",
"      </a>",
"      ]. The morbidity rates for planned vaginal and planned cesarean delivery were 15.1 and 7.4 percent, respectively (OR 1.11, 95% CI 0.65&ndash;1.88); mortality rates were 0.7 and 0.1 percent, respectively (OR 3.04; 95% CI 0.37&ndash;25.2).",
"     </li>",
"     <li>",
"      A decision analysis based on data from a cohort of 2597 twin pregnancies &ge;34 weeks with the first twin in cephalic presentation concluded a strategy of planned vaginal delivery was preferable [",
"      <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Better data on which to base a recommendation for the optimal route of delivery for twins will be provided by the Twin Birth Study, an ongoing international trial of 2400 twin pregnancies randomly assigned to deliver vaginally or by cesarean.",
"   </p>",
"   <p>",
"    We do not favor a policy of planned cesarean delivery of all twin pregnancies. With appropriate intrapartum monitoring and management (see below), the second twin is not at high risk of neonatal mortality or morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/53\">",
"     53",
"    </a>",
"    ]. We choose a delivery route based upon presentation, gestational age, and amnionicity (see below), as well as the",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of standard obstetrical indications for cesarean delivery (eg, placenta previa).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Should VLBW fetuses be delivered by cesarean?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators have suggested that cesarean delivery may decrease the risk of intracranial hemorrhage in very low birth weight (VLBW) preterm twin fetuses, regardless of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. We and others have not found adequate evidence to recommend a policy of elective cesarean delivery of VLBW babies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20374?source=see_link\">",
"     \"Intrapartum management of the low birthweight vertex fetus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of fetal presentation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Vertex-vertex twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;This presentation accounts for approximately 42 percent of twins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/57\">",
"     57",
"    </a>",
"    ]. The general consensus is that a trial of labor with the goal of a vaginal delivery of vertex-vertex twins is appropriate at any gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/6,58\">",
"     6,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nonvertex presenting twin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonvertex first twin comprises approximately 20 percent of twin presentations. Breech presenting twins are paired with vertex twins (7 percent), breech twins (6 percent), and transverse twins (5 percent); breech-oblique, transverse-vertex, and transverse&ndash;transverse presentations each comprise fewer than 1 percent of twins. A unique, potential complication of breech-vertex twin delivery, as opposed to breech singleton delivery, is the possibility of interlocking chins (ie, locked twins), but this is rare.",
"   </p>",
"   <p>",
"    A retrospective case-control analysis of data from 13 centers that allowed vaginal birth for breech first twins reported no difference in Apgar scores and neonatal mortality related to route of delivery among infants weighing more than 1500 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/59\">",
"     59",
"    </a>",
"    ]. However, nonvertex presenting fetuses weighing less than 1500 grams that were delivered vaginally had significantly higher rates of low Apgar scores and neonatal mortality compared to those delivered by cesarean (37 versus 20 percent and 45 versus 8 percent, respectively).",
"   </p>",
"   <p>",
"    In contrast to this report, we and others suggest cesarean delivery when the first twin is not in the vertex presentation because the safety of vaginal delivery in these cases has not been confirmed by randomized trials and the general consensus in the obstetric community is against vaginal delivery of the breech presenting fetus, even in singleton pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/58,60\">",
"     58,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=see_link\">",
"     \"Delivery of the fetus in breech presentation\"",
"    </a>",
"    .) An exception is the breech presenting second twin (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Vertex-nonvertex twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertex-nonvertex twins comprise 38 percent of twins; the nonvertex twin may be breech (26 percent), transverse (11 percent), or oblique (1 percent). Options for delivery include cesarean delivery of both twins, vaginal delivery with cephalic version of the second twin, or vaginal delivery with breech extraction of the second twin.",
"   </p>",
"   <p>",
"    The only randomized trial of planned vaginal versus abdominal birth was performed in 60 women with vertex-nonvertex twins at 35 to 42 weeks of gestation and otherwise uncomplicated pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/61\">",
"     61",
"    </a>",
"    ]. Maternal morbidity was higher with planned cesarean delivery, with no difference in neonatal outcome. However, this trial was too small to detect clinically important differences in outcome between the two groups.",
"   </p>",
"   <p>",
"    Many studies have reported successful vaginal delivery of both twins using internal or external version or breech extraction of the second twin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/62-78\">",
"     62-78",
"    </a>",
"    ]. The second twins of vertex-nonvertex and vertex-vertex pairs generally had similar neonatal outcomes irrespective of mode of delivery or procedures performed during delivery, but these series were small and observational. Successful vaginal delivery appeared to be less likely when external version was attempted than when breech extraction was performed immediately after delivery of the presenting twin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/64,65,72,76\">",
"     64,65,72,76",
"    </a>",
"    ]; external version was completed in 40 to 50 percent of cases (the remainder were delivered by cesarean delivery), while breech extraction followed by vaginal birth succeeded in 96 to 100 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Of note, the mean gestational age was approximately 34 to 35 weeks and the mean birthweight was 2100 to 2200 grams in these studies; 7 to 15 percent of the neonates weighed less than 1500 grams.",
"   </p>",
"   <p>",
"    In contrast, a population based cohort study of twin deliveries in the United States reported infants weighing 1500 to 4000 grams had a significantly higher frequency of neonatal death (adjusted for anomalies), asphyxia, and injury when both twins of a vertex-nonvertex pair were delivered vaginally than when both twins were delivered by cesarean [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/79\">",
"     79",
"    </a>",
"    ]. Interpretation of these data is limited because it was obtained from birth certificates.",
"   </p>",
"   <p>",
"    In the absence of good data favoring one approach over another, we suggest offering the patient an attempt at breech extraction of the second twin and proceeding to cesarean delivery if unsuccessful. If the patient does not wish to attempt breech extraction of the second twin, we give her the option of attempting external cephalic version of the second twin or undergoing cesarean delivery of both twins. When discussing the options of breech extraction or external cephalic version with patients, the obstetrician should include information about his or her experience and comfort with these procedures. Many obstetricians, based on training and experience, may feel more comfortable performing cesarean delivery. Under these circumstances, cesarean delivery of both twins is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159562333\">",
"    <span class=\"h4\">",
"     Contraindications to breech extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally do not offer the option of breech extraction when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated fetal weight of the second twin is &ge;20 percent more than that of the presenting twin.",
"     </li>",
"     <li>",
"      The delivery of the presenting twin suggests that the pelvis may not be adequate for a breech delivery, such as when there is a prolonged second stage or marked molding of the head.",
"     </li>",
"     <li>",
"      The gestational age is less than 28 weeks or the estimated fetal weight of the second twin is less than 1500 grams. Under these circumstances, we recommend performing cesarean delivery of both twins, rather than attempting cephalic version of the nonvertex second twin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Trial of labor after previous cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient data to establish the safety of attempting vaginal birth of twins after a previous low transverse cesarean delivery. Available data are reassuring that outcomes are similar to those in women with singletons undergoing a trial of labor. One of the largest series reported uterine rupture in 16 of 1850 women with twins (0.9 percent) undergoing a trial of labor after previous cesarean delivery; this rate was comparable to that in singleton pregnancies undergoing trial of labor (0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/80\">",
"     80",
"    </a>",
"    ]. Successful vaginal delivery was achieved in 45 percent of the twin gestations and 62 percent of the singletons. Smaller series have reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/81-87\">",
"     81-87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is our practice to offer a trial of labor to women with twin pregnancies and one prior cesarean delivery, provided they go into spontaneous labor. Because the most common initial sign of uterine rupture is fetal heart rate changes, we continually monitor both fetuses. If this is not technically possible, then cesarean delivery is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monoamniotic twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The route of delivery of monoamniotic twins is considered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43511?source=see_link\">",
"     \"Monoamniotic twin pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear whether multiple gestation has an effect on the progress of labor; studies have reported conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    for augmentation or induction of labor appears to be effective; there are inadequate data to allow evaluation of safety [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/90-93\">",
"     90-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Electronic fetal heart rate monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple gestations are at increased risk of intrapartum complications; therefore, we monitor both twins continuously during labor. Intermittent auscultation is not practical and may not reliably distinguish one twin from the other.",
"   </p>",
"   <p>",
"    The fetal heart rate of each twin can be monitored using a single machine (",
"    <a class=\"graphic graphic_waveform graphicRef68893 \" href=\"UTD.htm?17/61/18384\">",
"     waveform 1",
"    </a>",
"    ). These rates are often synchronous, thus requiring frequent careful review of the tracing to make sure each fetus' heart rate is being monitored. Ultrasound can assist in ensuring that both fetal heart rates are traced. If separate monitors are used, internal clocks must be synchronized, paper speeds must be identical, and contractions must be displayed on both tracings.",
"   </p>",
"   <p>",
"    Electronic fetal heart rate monitoring is particularly useful for assessing the well-being of the second twin during the high risk period after delivery of the first twin (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Interval between delivery of the two twins'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Analgesia and anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    is generally recommended because it provides good pain relief, does not cause neonatal depression, and is a suitable anesthetic if uterine manipulation (eg, version) or operative delivery (eg, forceps, cesarean) become necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     First twin",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a variety of reasons, morbidity and mortality tend to be lower in first born than second born twins, regardless of route of delivery. A systematic review of observational studies reported the overall neonatal morbidity of first and second twins was 3.0 and 4.6 percent, respectively (OR 0.53, 95% CI 0.39-0.70), and overall neonatal mortality was 0.3 and 0.6 percent, respectively (OR 0.55, 95% CI 0.38-0.81) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When vaginal birth is attempted, the capacity for immediate cesarean delivery is important in the event that complications necessitating urgent delivery arise (eg, prolapsed umbilical cord, nonreassuring fetal heart rate, or failed breech",
"    <span class=\"nowrap\">",
"     extraction/cephalic",
"    </span>",
"    version). Emergency cesarean delivery has been reported in 10 to 30 percent of pregnancies in which vaginal births of twins had been planned, and may be necessary for delivery of the second twin after vaginal birth of the first twin (see below). It is our practice to deliver all twin pregnancies in an operating room where cesarean delivery can be performed. In our hospital, patients are moved to the operating room in the second stage of labor. However, if a patient can be transported to an operating room rapidly, delivery of vertex-vertex twins in a labor room is not unreasonable.",
"   </p>",
"   <p>",
"    Delivery of the first twin of a diamniotic pair is similar to delivery of a singleton except the umbilical cords should be marked with progressive numbers of clamps (eg, one for the first twin birth, two for the second twin birth). If surgical clamps are used initially, they should be replaced with a like number of plastic umbilical cord clamps prior to sending the placenta for formal examination. Recall that 'twin A' on ultrasound may not be first born at delivery (especially if the delivery is by cesarean), and this infant is typically called 'baby A' by delivery room and nursery personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/94-97\">",
"     94-97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Second twin",
"    </span>",
"    &nbsp;&mdash;&nbsp;After delivery of the first twin, the heart rate and position of the second twin should be evaluated using ultrasound and electronic fetal monitoring. If the second twin is in a nonvertex presentation, ultrasound can be used to assist external cephalic version, breech extraction, or internal podalic version of the second twin, if necessary.",
"   </p>",
"   <p>",
"    As discussed above, our preference is breech extraction if the second twin is not in a vertex presentation and there are no contraindications to breech extraction (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Vertex-nonvertex twins'",
"    </a>",
"    above). Intrauterine manipulation is aided by ultrasonographic visualization of the orientation between the physician's hands and fetal parts (",
"    <a class=\"graphic graphic_figure graphicRef58961 graphicRef71779 \" href=\"UTD.htm?4/30/4584\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/98\">",
"     98",
"    </a>",
"    ] and can be facilitated by administering intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or inhalational anesthesia, which relax uterine muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/99\">",
"     99",
"    </a>",
"    ]. Effective maternal analgesia is also crucial. When the fetus is in the desired presentation for delivery,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is given if labor has not resumed. Amniotomy is avoided until after the presenting part is engaged [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/51,100\">",
"     51,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others have taken a somewhat different approach. One historic cohort study of 130 planned vaginal twin deliveries reported no patient who had a vaginal delivery of the first twin required cesarean delivery of the second twin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/78\">",
"     78",
"    </a>",
"    ]. In this group's practice, all patients who were undelivered at 38 weeks of gestation underwent induction if they met strict criteria (estimated weight of the second twin &ge;1500 g and no more than 20 percent greater than the weight of the presenting twin, absence of usual contraindications to vaginal delivery). After vaginal birth of the first twin, the second twin was delivered as a vertex presentation if the vertex was engaged immediately after delivery of the first twin, by breech extraction if in breech presentation after delivery of the first twin, and by breech extraction after internal podalic version if in vertex presentation but unengaged after delivery of the first twin. The authors attributed their success to active management of the second stage of labor by obstetricians experienced in breech delivery and internal podalic version, and to their criteria for selecting candidates for vaginal delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Interval between delivery of the two twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, second born twins were reported to have a higher incidence of adverse outcome (morbidity and mortality) due to lower birth weight; higher frequency of malpresentation, cord prolapse, and abruptio placentae; and more deliveries involving internal podalic version. A prolonged interval between delivery of the first and second twins was also thought to be associated with poorer outcomes. Intervals of less than 25 to 30 minutes were advocated, and maneuvers such as internal podalic version or breech extraction of the second twin were often recommended to hasten delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent studies undertaken after the universal routine use of electronic fetal monitoring during labor suggest that there does not have to be a finite interval between delivery of the first and second twin, as long as the fetal heart rate tracing is reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. Electronic fetal monitoring and the availability of real-time ultrasound have enabled obstetricians to identify those second twins who would benefit from expedited delivery, while allowing most cases to be managed expectantly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/105\">",
"     105",
"    </a>",
"    ]. Thus, spontaneous delivery of both twins is more likely to be achieved.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    augmentation of labor after delivery of the first twin is reasonable and sometimes necessary due to a temporary reduction in contraction frequency after the first birth [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed-interval delivery in previable gestations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5510?source=see_link\">",
"     \"Delayed-interval delivery in multifetal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Unplanned cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unplanned cesarean for delivery of the second twin is not uncommon, occurring in about 4 to 10 percent of planned vaginal births [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. As an example, a population based cohort study of twin deliveries in the United States reported 9.5 percent of second twins were delivered by cesarean after vaginal birth of the first twin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/107\">",
"     107",
"    </a>",
"    ]. This rate fell to 6.3 percent if the second twin was vertex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/110\">",
"     110",
"    </a>",
"    ], but increased to 24.8 percent if only vertex-nonvertex live births were considered [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis including over 39,000 twins sets found that for the second twin, morbidity following combined delivery (19.8 percent) was higher than after vaginal delivery (9.5 percent; OR 0.55, 95% CI 0.41-0.74) or cesarean delivery (9.8 percent; OR 0.47, 95% CI 0.43-0.53) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/50\">",
"     50",
"    </a>",
"    ]. Factors related to unplanned cesarean for delivery of the second twin likely account for the increased morbidity. In combined deliveries, there may be an increased risk of maternal or neonatal infection due to exposure to labor and ruptured membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1584079532\">",
"    <span class=\"h1\">",
"     EXAMINATION OF THE PLACENTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the placenta can help to determine zygosity and the pathogenesis of neonatal findings (eg, discordant growth, structural anomalies, or infection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=see_link\">",
"     \"Gross examination of the placenta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1584080997\">",
"    <span class=\"h2\">",
"     Monozygotic or dizygotic?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately two-thirds of naturally-conceived twins are dizygotic. It is of importance to parents and twins to know whether same sex twins are monozygotic (in lay terms, \"identical\"). Based upon a genotype and placental study of 668 consecutive twin pairs in Birmingham, England, parents can be informed in the delivery room that 37 percent of all same sex twins are \"identical\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/111\">",
"     111",
"    </a>",
"    ]. Same sex twins are virtually always \"identical\" if monochorionic, while 18 percent of same sex twins with dichorionic membranes are \"identical\" (",
"    <a class=\"graphic graphic_figure graphicRef53594 \" href=\"UTD.htm?12/44/12992\">",
"     figure 2",
"    </a>",
"    ). However, these proportions may not be accurate for pregnancies conceived through in vitro fertilization, in which the rate of monozygotic twinning appears to be higher than in spontaneously conceived pregnancies (2.3 versus 0.4 percent of pregnancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/112\">",
"     112",
"    </a>",
"    ]. In addition, there are several reported cases of dizygotic twins with monochorionic placentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/113-115\">",
"     113-115",
"    </a>",
"    ]. The mechanism has not been explained, but may have been related to assisted reproductive technology.",
"   </p>",
"   <p>",
"    Zygosity can be determined conclusively using blood type or DNA markers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1584081134\">",
"    <span class=\"h2\">",
"     Vascular anastomoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In monochorionic twins, vascular anastomoses are evaluated by placental injection. This study takes about an hour to perform and involves catheterizing the arteries and vein of each umbilical cord and injecting the vessels with a substance, such as dyed undiluted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    sulfate, until the peripheral branches are filled and backpressure prevents further injection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/117\">",
"     117",
"    </a>",
"    ]. The amniotic membranes are then removed from the chorionic surface and the placenta is rinsed with cold tap water to improve visualization of the number and type of anastomoses. Several arteriovenous and venoarterial anastomoses in combination with an arterioarterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venovenous anastomosis are seen in 90 percent of placentas. The remaining 10 percent are equally divided between those with only arteriovenous anastomoses and those with no anastomoses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/11/5306/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=see_link\">",
"       \"Patient information: Having twins (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest avoiding elective delivery of",
"      <span class=\"nowrap\">",
"       dichorionic/diamniotic",
"      </span>",
"      twins prior to 38 weeks or after 40 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest delivery of",
"      <span class=\"nowrap\">",
"       monochorionic/diamniotic",
"      </span>",
"      twins at 36 to 37 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For vertex-vertex twins, we suggest vaginal delivery in the absence of standard indications for cesarean delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vertex-vertex twins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the first twin is not in vertex presentation, we suggest cesarean delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nonvertex presenting twin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For vertex-nonvertex twins, we suggest breech extraction of the second twin only if the obstetrician has the requisite experience and if the patient provides informed consent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Vertex-nonvertex twins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available data are reassuring that outcomes in women with twins attempting vaginal birth after a previous cesarean delivery are similar to those with singletons undergoing a trial of labor. However, these data are insufficient to definitively establish that uterine rupture rates are comparable. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Trial of labor after previous cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       Oxytocin",
"      </a>",
"      for augmentation or induction of labor appears to be effective in twin gestations; there are inadequate data to establish the safety of this intervention. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Labor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest continuous electronic fetal monitoring of both fetuses during labor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Electronic fetal heart rate monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest epidural",
"      <span class=\"nowrap\">",
"       analgesia/anesthesia",
"      </span>",
"      during labor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Analgesia and anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After delivery of the first twin, the heart rate and position of the second twin should be evaluated using ultrasound and electronic fetal monitoring. As long as the fetal heart rate tracing is reassuring, there is no duration of elapsed time from delivery of the first twin that necessitates intervention to deliver the second twin. Six to 25 percent of second twins will be delivered by cesarean after vaginal delivery of the first twin. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Second twin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 18 percent of naturally-conceived same sex twins with dichorionic membranes are \"identical.\" (see",
"      <a class=\"local\" href=\"#H1584080997\">",
"       'Monozygotic or dizygotic?'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/1\">",
"      Kogan MD, Alexander GR, Kotelchuck M, et al. Trends in twin birth outcomes and prenatal care utilization in the United States, 1981-1997. JAMA 2000; 284:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/2\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     Multiple pregnancy: The management of twin and triplet pregnancies in the antenatal period file://publications.nice.org.uk/multiple-pregnancy-cg129 (Accessed on April 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/4\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/5\">",
"      Chasen ST, Madden A, Chervenak FA. Cesarean delivery of twins and neonatal respiratory disorders. Am J Obstet Gynecol 1999; 181:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/6\">",
"      Cruikshank DP. Intrapartum management of twin gestations. Obstet Gynecol 2007; 109:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/7\">",
"      Breathnach FM, McAuliffe FM, Geary M, et al. Optimum timing for planned delivery of uncomplicated monochorionic and dichorionic twin pregnancies. Obstet Gynecol 2012; 119:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/8\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 97: Fetal lung maturity. Obstet Gynecol 2008; 112:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/9\">",
"      Luke B. Reducing fetal deaths in multiple births: optimal birthweights and gestational ages for infants of twin and triplet births. Acta Genet Med Gemellol (Roma) 1996; 45:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/10\">",
"      Minakami H, Sato I. Reestimating date of delivery in multifetal pregnancies. JAMA 1996; 275:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/11\">",
"      Sairam S, Costeloe K, Thilaganathan B. Prospective risk of stillbirth in multiple-gestation pregnancies: a population-based analysis. Obstet Gynecol 2002; 100:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/12\">",
"      Kahn B, Lumey LH, Zybert PA, et al. Prospective risk of fetal death in singleton, twin, and triplet gestations: implications for practice. Obstet Gynecol 2003; 102:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/13\">",
"      Suzuki S, Otsubo Y, Sawa R, et al. Clinical trial of induction of labor versus expectant management in twin pregnancy. Gynecol Obstet Invest 2000; 49:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/14\">",
"      Dodd JM, Crowther CA, Haslam RR, et al. Elective birth at 37 weeks of gestation versus standard care for women with an uncomplicated twin pregnancy at term: the Twins Timing of Birth Randomised Trial. BJOG 2012; 119:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/15\">",
"      Luke B, Minogue J, Witter FR, et al. The ideal twin pregnancy: patterns of weight gain, discordancy, and length of gestation. Am J Obstet Gynecol 1993; 169:588.",
"     </a>",
"    </li>",
"    <li>",
"     Cincotta, RB, Flenady, V, Hockey, R, King, J. When should twins be delivered? Gestational age-specific stillbirth risk of twins vs singletons. Perinatal Society of Australia and New Zealand, 5th annual congress, 2001 March 13-16, Canberra, Australia 2001:22.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/17\">",
"      Cheung YB, Yip P, Karlberg J. Mortality of twins and singletons by gestational age: a varying-coefficient approach. Am J Epidemiol 2000; 152:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/18\">",
"      Hartley RS, Emanuel I, Hitti J. Perinatal mortality and neonatal morbidity rates among twin pairs at different gestational ages: optimal delivery timing at 37 to 38 weeks' gestation. Am J Obstet Gynecol 2001; 184:451.",
"     </a>",
"    </li>",
"    <li>",
"     Dodd, JM, Robinson, JS, Crowther, CA, et al. Stillbirth and neonatal outcomes in twin and singleton pregnancies in South Australia, 1991-2000. Perinatal Society of Australia and New Zealand 6th Annual Congress; 2002 March 9-13. Australia, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/20\">",
"      Luke B, Brown MB, Alexandre PK, et al. The cost of twin pregnancy: maternal and neonatal factors. Am J Obstet Gynecol 2005; 192:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/21\">",
"      Cheung, YB, Yip, P, Karlberg, J. Mortality of twins and singletons by gestational age: a varying coefficient approach. Am J Epidemiol 2000; 152:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/22\">",
"      Dodd JM, Robinson JS, Crowther CA, Chan A. Stillbirth and neonatal outcomes in South Australia, 1991-2000. Am J Obstet Gynecol 2003; 189:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/23\">",
"      Bakr AF, Karkour T. What is the optimal gestational age for twin delivery. BMC Pregnancy Childbirth 2006; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/24\">",
"      Udom-Rice I, Inglis SR, Skupski D, et al. Optimal gestational age for twin delivery. J Perinatol 2000; 20:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/25\">",
"      American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics, Society for Maternal-Fetal Medicine, ACOG Joint Editorial Committee. ACOG Practice Bulletin #56: Multiple gestation: complicated twin, triplet, and high-order multifetal pregnancy. Obstet Gynecol 2004; 104:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/26\">",
"      Soucie JE, Yang Q, Wen SW, et al. Neonatal mortality and morbidity rates in term twins with advancing gestational age. Am J Obstet Gynecol 2006; 195:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/27\">",
"      Leveno KJ, Quirk JG, Whalley PJ, et al. Fetal lung maturation in twin gestation. Am J Obstet Gynecol 1984; 148:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/28\">",
"      Winn HN, Romero R, Roberts A, et al. Comparison of fetal lung maturation in preterm singleton and twin pregnancies. Am J Perinatol 1992; 9:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/29\">",
"      Friedman SA, Schiff E, Kao L, et al. Do twins mature earlier than singletons? Results from a matched cohort study. Am J Obstet Gynecol 1997; 176:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/30\">",
"      Marttila R, Kaprio J, Hallman M. Respiratory distress syndrome in twin infants compared with singletons. Am J Obstet Gynecol 2004; 191:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/31\">",
"      Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995; 102:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/32\">",
"      Blickstein I. Cesarean section for all twins? J Perinat Med 2000; 28:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/33\">",
"      Lewis DF, Fontenot MT, Robichaux AG, et al. Respiratory morbidity in well-dated twins approaching term. What are the risks of elective delivery? J Reprod Med 2002; 47:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/34\">",
"      Mackenzie MW. Predicting concordance of biochemical lung maturity in the preterm twin gestation. J Matern Fetal Neonatal Med 2002; 12:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/35\">",
"      Whitworth NS, Magann EF, Morrison JC. Evaluation of fetal lung maturity in diamniotic twins. Am J Obstet Gynecol 1999; 180:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/36\">",
"      Cleary-Goldman J, D'Alton ME. Uncomplicated monochorionic diamniotic twins and the timing of delivery. PLoS Med 2005; 2:e180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/37\">",
"      Sim&otilde;es T, Amaral N, Lerman R, et al. Prospective risk of intrauterine death of monochorionic-diamniotic twins. Am J Obstet Gynecol 2006; 195:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/38\">",
"      Barigye O, Pasquini L, Galea P, et al. High risk of unexpected late fetal death in monochorionic twins despite intensive ultrasound surveillance: a cohort study. PLoS Med 2005; 2:e172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/39\">",
"      Hack KE, Derks JB, Elias SG, et al. Increased perinatal mortality and morbidity in monochorionic versus dichorionic twin pregnancies: clinical implications of a large Dutch cohort study. BJOG 2008; 115:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/40\">",
"      Sullivan AE, Hopkins PN, Weng HY, et al. Delivery of monochorionic twins in the absence of complications: analysis of neonatal outcomes and costs. Am J Obstet Gynecol 2012; 206:257.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/41\">",
"      Hack KE, Derks JB, Elias SG, et al. Perinatal mortality and mode of delivery in monochorionic diamniotic twin pregnancies &ge; 32 weeks of gestation: a multicentre retrospective cohort study. BJOG 2011; 118:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/42\">",
"      Robinson BK, Miller RS, D'Alton ME, Grobman WA. Effectiveness of timing strategies for delivery of monochorionic diamniotic twins. Am J Obstet Gynecol 2012; 207:53.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/43\">",
"      Beasley E, Megerian G, Gerson A, Roberts NS. Monoamniotic twins: case series and proposal for antenatal management. Obstet Gynecol 1999; 93:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/44\">",
"      Rodis JF, McIlveen PF, Egan JF, et al. Monoamniotic twins: improved perinatal survival with accurate prenatal diagnosis and antenatal fetal surveillance. Am J Obstet Gynecol 1997; 177:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/45\">",
"      Steer P. Perinatal death in twins. BMJ 2007; 334:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/46\">",
"      Smith GC, Shah I, White IR, et al. Mode of delivery and the risk of delivery-related perinatal death among twins at term: a retrospective cohort study of 8073 births. BJOG 2005; 112:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/47\">",
"      Smith GC, Fleming KM, White IR. Birth order of twins and risk of perinatal death related to delivery in England, Northern Ireland, and Wales, 1994-2003: retrospective cohort study. BMJ 2007; 334:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/48\">",
"      Meyer MC. Translating data to dialogue: how to discuss mode of delivery with your patient with twins. Am J Obstet Gynecol 2006; 195:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/49\">",
"      Hogle KL, Hutton EK, McBrien KA, et al. Cesarean delivery for twins: a systematic review and meta-analysis. Am J Obstet Gynecol 2003; 188:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/50\">",
"      Rossi AC, Mullin PM, Chmait RH. Neonatal outcomes of twins according to birth order, presentation and mode of delivery: a systematic review and meta-analysis. BJOG 2011; 118:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/51\">",
"      Vendittelli F, Rivi&egrave;re O, Crenn-H&eacute;bert C, et al. Is a planned cesarean necessary in twin pregnancies? Acta Obstet Gynecol Scand 2011; 90:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/52\">",
"      Hofmeyr GJ, Barrett JF, Crowther CA. Planned caesarean section for women with a twin pregnancy. Cochrane Database Syst Rev 2011; :CD006553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/53\">",
"      Sibony O, Touitou S, Luton D, et al. A comparison of the neonatal morbidity of second twins to that of a low-risk population. Eur J Obstet Gynecol Reprod Biol 2003; 108:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/54\">",
"      Zhang J, Bowes WA Jr, Grey TW, McMahon MJ. Twin delivery and neonatal and infant mortality: a population-based study. Obstet Gynecol 1996; 88:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/55\">",
"      Barrett JM, Staggs SM, Van Hooydonk JE, et al. The effect of type of delivery upon neonatal outcome in premature twins. Am J Obstet Gynecol 1982; 143:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/56\">",
"      Alfirevic Z, Milan SJ, Livio S. Caesarean section versus vaginal delivery for preterm birth in singletons. Cochrane Database Syst Rev 2012; 6:CD000078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/57\">",
"      Chasen ST, Spiro SJ, Kalish RB, Chervenak FA. Changes in fetal presentation in twin pregnancies. J Matern Fetal Neonatal Med 2005; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/58\">",
"      Dodd JM, Crowther CA. Evidence-based care of women with a multiple pregnancy. Best Pract Res Clin Obstet Gynaecol 2005; 19:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/59\">",
"      Blickstein I, Goldman RD, Kupferminc M. Delivery of breech first twins: a multicenter retrospective study. Obstet Gynecol 2000; 95:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/60\">",
"      Arabin B, Kyvernitakis I. Vaginal delivery of the second nonvertex twin: avoiding a poor outcome when the presenting part is not engaged. Obstet Gynecol 2011; 118:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/61\">",
"      Rabinovici J, Barkai G, Reichman B, et al. Randomized management of the second nonvertex twin: vaginal delivery or cesarean section. Am J Obstet Gynecol 1987; 156:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/62\">",
"      Chervenak FA, Johnson RE, Berkowitz RL, Hobbins JC. Intrapartum external version of the second twin. Obstet Gynecol 1983; 62:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/63\">",
"      Chervenak FA, Johnson RE, Youcha S, et al. Intrapartum management of twin gestation. Obstet Gynecol 1985; 65:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/64\">",
"      Mauldin JG, Newman RB, Mauldin PD. Cost-effective delivery management of the vertex and nonvertex twin gestation. Am J Obstet Gynecol 1998; 179:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/65\">",
"      Chauhan SP, Roberts WE, McLaren RA, et al. Delivery of the nonvertex second twin: breech extraction versus external cephalic version. Am J Obstet Gynecol 1995; 173:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/66\">",
"      Davison L, Easterling TR, Jackson JC, Benedetti TJ. Breech extraction of low-birth-weight second twins: can cesarean section be justified? Am J Obstet Gynecol 1992; 166:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/67\">",
"      Morales WJ, O'Brien WF, Knuppel RA, et al. The effect of mode of delivery on the risk of intraventricular hemorrhage in nondiscordant twin gestations under 1500 g. Obstet Gynecol 1989; 73:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/68\">",
"      Winn HN, Cimino J, Powers J, et al. Intrapartum management of nonvertex second-born twins: a critical analysis. Am J Obstet Gynecol 2001; 185:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/69\">",
"      Acker D, Lieberman M, Holbrook RH, et al. Delivery of the second twin. Obstet Gynecol 1982; 59:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/70\">",
"      Blickstein I, Schwartz-Shoham Z, Lancet M, Borenstein R. Vaginal delivery of the second twin in breech presentation. Obstet Gynecol 1987; 69:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/71\">",
"      Rabinovici J, Barkai G, Reichman B, et al. Internal podalic version with unruptured membranes for the second twin in transverse lie. Obstet Gynecol 1988; 71:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/72\">",
"      Gocke SE, Nageotte MP, Garite T, et al. Management of the nonvertex second twin: primary cesarean section, external version, or primary breech extraction. Am J Obstet Gynecol 1989; 161:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/73\">",
"      Adam C, Allen AC, Baskett TF. Twin delivery: influence of the presentation and method of delivery on the second twin. Am J Obstet Gynecol 1991; 165:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/74\">",
"      Fishman A, Grubb DK, Kovacs BW. Vaginal delivery of the nonvertex second twin. Am J Obstet Gynecol 1993; 168:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/75\">",
"      Kaplan B, Peled Y, Rabinerson D, et al. Successful external version of B-twin after the birth of A-twin for vertex--non-vertex twins. Eur J Obstet Gynecol Reprod Biol 1995; 58:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/76\">",
"      Wells SR, Thorp JM Jr, Bowes WA Jr. Management of the nonvertex second twin. Surg Gynecol Obstet 1991; 172:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/77\">",
"      Peaceman AM, Kuo L, Feinglass J. Infant morbidity and mortality associated with vaginal delivery in twin gestations. Am J Obstet Gynecol 2009; 200:462.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/78\">",
"      Fox NS, Silverstein M, Bender S, et al. Active second-stage management in twin pregnancies undergoing planned vaginal delivery in a U.S. population. Obstet Gynecol 2010; 115:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/79\">",
"      Yang Q, Wen SW, Chen Y, et al. Neonatal death and morbidity in vertex-nonvertex second twins according to mode of delivery and birth weight. Am J Obstet Gynecol 2005; 192:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/80\">",
"      Ford AA, Bateman BT, Simpson LL. Vaginal birth after cesarean delivery in twin gestations: a large, nationwide sample of deliveries. Am J Obstet Gynecol 2006; 195:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/81\">",
"      Miller DA, Mullin P, Hou D, Paul RH. Vaginal birth after cesarean section in twin gestation. Am J Obstet Gynecol 1996; 175:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/82\">",
"      Sansregret A, Bujold E, Gauthier RJ. Twin delivery after a previous caesarean: a twelve-year experience. J Obstet Gynaecol Can 2003; 25:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/83\">",
"      Delaney T, Young DC. Trial of labour compared to elective Caesarean in twin gestations with a previous Caesarean delivery. J Obstet Gynaecol Can 2003; 25:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/84\">",
"      Myles T. Vaginal birth of twins after a previous Cesarean section. J Matern Fetal Med 2001; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/85\">",
"      Odeh M, Tarazova L, Wolfson M, Oettinger M. Evidence that women with a history of cesarean section can deliver twins safely. Acta Obstet Gynecol Scand 1997; 76:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/86\">",
"      Strong TH Jr, Phelan JP, Ahn MO, Sarno AP Jr. Vaginal birth after cesarean delivery in the twin gestation. Am J Obstet Gynecol 1989; 161:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/87\">",
"      Cahill A, Stamilio DM, Par&eacute; E, et al. Vaginal birth after cesarean (VBAC) attempt in twin pregnancies: is it safe? Am J Obstet Gynecol 2005; 193:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/88\">",
"      Silver RK, Haney EI, Grobman WA, et al. Comparison of active phase labor between triplet, twin, and singleton gestations. J Soc Gynecol Investig 2000; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/89\">",
"      Schiff E, Cohen SB, Dulitzky M, et al. Progression of labor in twin versus singleton gestations. Am J Obstet Gynecol 1998; 179:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/90\">",
"      Fausett MB, Barth WH Jr, Yoder BA, Satin AJ. Oxytocin labor stimulation of twin gestations: effective and efficient. Obstet Gynecol 1997; 90:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/91\">",
"      Neimand KM, Gibstein A, Rosenthal AH. Oxytocin in twin gestation. Am J Obstet Gynecol 1967; 99:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/92\">",
"      Fleming AD, Rayburn WF, Mandsager NT, et al. Perinatal outcomes of twin pregnancies at term. J Reprod Med 1990; 35:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/93\">",
"      Leroy F. Oxytocin treatment in twin pregnancy labour. Acta Genet Med Gemellol (Roma) 1979; 28:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/94\">",
"      Dias T, Ladd S, Mahsud-Dornan S, et al. Systematic labeling of twin pregnancies on ultrasound. Ultrasound Obstet Gynecol 2011; 38:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/95\">",
"      Bronshtein M, Bar-Hava I, Ben-Rafael Z, et al. Twin gestation: is there a correlation between the location of the gestational sacs at the beginning of pregnancy, and the order of delivery. Eur J Obstet Gynecol Reprod Biol 1998; 77:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/96\">",
"      Chasen ST, Al-Kouatly HB, Chervenak FA. Correlation between prenatal and neonatal birth order in twin pregnancy. Am J Perinatol 2001; 18:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/97\">",
"      D'Antonio F, Dias T, B. Thilaganathan on behalf of the Southwest Thames Obstetric Research Collaborative (STORK). Does antenatal ultrasound labeling predict birth order in twin pregnancies? Ultrasound Obstet Gynecol 2013; 41:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/98\">",
"      G&ouml;rbe E, Chasen S, Harmath A, et al. Very-low-birthweight breech infants: short-term outcome by method of delivery. J Matern Fetal Med 1997; 6:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/99\">",
"      Dufour P, Vinatier D, Vanderstichele S, et al. Intravenous nitroglycerin for internal podalic version of the second twin in transverse lie. Obstet Gynecol 1998; 92:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/100\">",
"      Caukwell S, Murphy DJ. The effect of mode of delivery and gestational age on neonatal outcome of the non-cephalic- presenting second twin. Am J Obstet Gynecol 2002; 187:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/101\">",
"      Thompson JP, Johnson CE. Survival and management of the second-born twin. Obstet Gynecol 1966; 27:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/102\">",
"      Second twin. Br Med J 1968; 2:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/103\">",
"      LITTLE WA, FRIEDMAN EA. The twin delivery: factors influencing second twin mortality. Obstet Gynecol Surv 1958; 13:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/104\">",
"      Rayburn WF, Lavin JP Jr, Miodovnik M, Varner MW. Multiple gestation: time interval between delivery of the first and second twins. Obstet Gynecol 1984; 63:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/105\">",
"      Rydhstr&ouml;m H, Ingemarsson I. Interval between birth of the first and the second twin and its impact on second twin perinatal mortality. J Perinat Med 1990; 18:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/106\">",
"      Brown HL, Miller JM Jr, Neumann DE, et al. Umbilical cord blood gas assessment of twins. Obstet Gynecol 1990; 75:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/107\">",
"      Wen SW, Fung KF, Oppenheimer L, et al. Occurrence and predictors of cesarean delivery for the second twin after vaginal delivery of the first twin. Obstet Gynecol 2004; 103:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/108\">",
"      Breathnach FM, McAuliffe FM, Geary M, et al. Prediction of safe and successful vaginal twin birth. Am J Obstet Gynecol 2011; 205:237.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/109\">",
"      Engelbrechtsen L, Nielsen EH, Perin T, et al. Cesarean Section for the Second Twin: A Population-Based Study of Occurrence and Outcome. Birth 2013; 40:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/110\">",
"      Yang Q, Wen SW, Chen Y, et al. Occurrence and clinical predictors of operative delivery for the vertex second twin after normal vaginal delivery of the first twin. Am J Obstet Gynecol 2005; 192:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/111\">",
"      Cameron AH. The Birmingham twin survey. Proc R Soc Med 1968; 61:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/112\">",
"      Blickstein I, Jones C, Keith LG. Zygotic-splitting rates after single-embryo transfers in in vitro fertilization. N Engl J Med 2003; 348:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/113\">",
"      Souter VL, Kapur RP, Nyholt DR, et al. A report of dizygous monochorionic twins. N Engl J Med 2003; 349:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/114\">",
"      Yoon G, Beischel LS, Johnson JP, Jones MC. Dizygotic twin pregnancy conceived with assisted reproductive technology associated with chromosomal anomaly, imprinting disorder, and monochorionic placentation. J Pediatr 2005; 146:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/115\">",
"      Miura K, Niikawa N. Do monochorionic dizygotic twins increase after pregnancy by assisted reproductive technology? J Hum Genet 2005; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/116\">",
"      Derom R, Bryan E, Derom C, et al. Twins, chorionicity and zygosity. Twin Res 2001; 4:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/117\">",
"      Lewi L, Deprest J, Hecher K. The vascular anastomoses in monochorionic twin pregnancies and their clinical consequences. Am J Obstet Gynecol 2013; 208:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/118\">",
"      Denbow ML, Cox P, Taylor M, et al. Placental angioarchitecture in monochorionic twin pregnancies: relationship to fetal growth, fetofetal transfusion syndrome, and pregnancy outcome. Am J Obstet Gynecol 2000; 182:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/11/5306/abstract/119\">",
"      Lewi L, Cannie M, Blickstein I, et al. Placental sharing, birthweight discordance, and vascular anastomoses in monochorionic diamniotic twin placentas. Am J Obstet Gynecol 2007; 197:587.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4467 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5306=[""].join("\n");
var outline_f5_11_5306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TIMING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dichorionic/diamniotic twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Optimal length of gestation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Assessment of pulmonary maturity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Upper gestational age limit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monochorionic/diamniotic twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Monoamniotic twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ROUTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Should routine cesarean delivery be offered?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Should VLBW fetuses be delivered by cesarean?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of fetal presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Vertex-vertex twins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nonvertex presenting twin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Vertex-nonvertex twins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1159562333\">",
"      Contraindications to breech extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Trial of labor after previous cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monoamniotic twins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Electronic fetal heart rate monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Analgesia and anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      First twin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Second twin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Interval between delivery of the two twins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Unplanned cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1584079532\">",
"      EXAMINATION OF THE PLACENTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1584080997\">",
"      Monozygotic or dizygotic?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1584081134\">",
"      Vascular anastomoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4467\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4467|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/55/7027\" title=\"figure 1A\">",
"      Internal podalic version",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/61/35794\" title=\"figure 1B\">",
"      Internal podalic version2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/44/12992\" title=\"figure 2\">",
"      Placenta and membranes in twin pregnancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4467|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/61/18384\" title=\"waveform 1\">",
"      Twins FHR tracings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=related_link\">",
"      Assessment of fetal lung maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=related_link\">",
"      Cesarean delivery: Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5510?source=related_link\">",
"      Delayed-interval delivery in multifetal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=related_link\">",
"      Delivery of the fetus in breech presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20374?source=related_link\">",
"      Intrapartum management of the low birthweight vertex fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9913?source=related_link\">",
"      Management of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43511?source=related_link\">",
"      Monoamniotic twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=related_link\">",
"      Neonatal outcome, complications, and management of multiple births",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=related_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_11_5307="Histologic features RB-ILD";
var content_f5_11_5307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic features of respiratory bronchiolitis pattern",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Key histologic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiolocentric alveolar macrophage accumulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild bronchiolar fibrosis and chronic inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macrophages have dusty brown cytoplasm (may be positive for iron stains)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pertinent negative findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of diffuse macrophage accumulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of interstitial fibrosis and/or honeycomb fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of fibroblast foci",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5307=[""].join("\n");
var outline_f5_11_5307=null;
var title_f5_11_5308="Vehicle selection";
var content_f5_11_5308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vehicle selection for specific body sites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vehicle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Smooth, nonhairy skin; thick,",
"hyperkeratotic lesions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hairy areas",
"       </td>",
"       <td class=\"subtitle1\">",
"        Palms, soles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infected areas",
"       </td>",
"       <td class=\"subtitle1\">",
"        Between skin folds; moist,",
"macerated lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: infrequently used; ++: acceptable vehicle; +++: preferred vehicle.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Goldstein, BG, Goldstein, AO, Practical Dermatology 2nd ed, Mosby-Year Book, Inc, St. Louis, MO, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5308=[""].join("\n");
var outline_f5_11_5308=null;
var title_f5_11_5309="Side effects of amiodarone";
var content_f5_11_5309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Type and incidence of major side effects associated with amiodarone therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"70%\">",
"     </colgroup>",
"     <colgroup width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Side effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Cough, especially with infiltrates on chest radiography and reduced DLCO",
"       </td>",
"       <td>",
"        5 to 15 (&gt;400 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2 (&le;400 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Thyroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Hypothyroidism and hyperthyroidism",
"       </td>",
"       <td>",
"        2 to 24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 4 (&le;400 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bradycardia and atrioventricular block",
"       </td>",
"       <td>",
"        3 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proarrhythmia",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum AST or ALT more than two times normal",
"       </td>",
"       <td>",
"        15 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 to 2 (&le;400 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis and cirrhosis",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Eye",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corneal microdeposits",
"       </td>",
"       <td>",
"        &gt;90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Halo vision, especially at night",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Optic neuritis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Photosensitivity",
"       </td>",
"       <td>",
"        25 to 75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blue discoloration",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Gastrointestinal tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Nausea, anorexia, and constipation",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 5 (&le;400 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Central nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Varied manifestations including ataxia, paresthesias, peripheral neuropathy, sleep disturbance, impaired memory, and tremor",
"       </td>",
"       <td>",
"        3 to 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 5 (&le;400 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Genitourinary tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epididymitis and erectile dysfunction",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741; Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997; 30:791; and Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126:63.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5309=[""].join("\n");
var outline_f5_11_5309=null;
var title_f5_11_5310="Abx for meningitis based on Gram stain";
var content_f5_11_5310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75922%7EID%2F60707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75922%7EID%2F60707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for antimicrobial therapy of bacterial meningitis in adults with presumptive pathogen identification by positive Gram stain*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Microorganism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alternative therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Vancomycin plus a third-generation cephalosporin&bull;&Delta;",
"       </td>",
"       <td>",
"        Fluoroquinolone&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"       </td>",
"       <td>",
"        Third-generation cephalosporin&bull;",
"       </td>",
"       <td>",
"        Chloramphenicol, fluoroquinolone, aztreonam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"       <td>",
"        Ampicillin&sect; or penicillin G&sect;",
"       </td>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"       </td>",
"       <td>",
"        Third-generation cephalosporin&bull;",
"       </td>",
"       <td>",
"        Chloramphenicol, cefepime, meropenem, fluoroquinolone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For recommended dosages, see the table \"Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis\".",
"     <br>",
"      &bull; Ceftriaxone or cefotaxime.",
"      <br>",
"       &Delta; Some experts would add rifampin if dexamethasone is also given.",
"       <br>",
"        &loz; Moxifloxacin is recommended given its excellent CSF penetration and in vitro activity against",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        , although there are no clinical data available. If used, many authorities would combine moxifloxacin with vancomycin or a third-generation cephalosporin (cefotaxime or ceftriaxone).",
"        <br>",
"         &sect; Addition of an aminoglycoside should be considered.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel, AR, Hartman, BJ, Kaplan, SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy;2004 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis who have normal renal and hepatic function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antimicrobial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin",
"       </td>",
"       <td>",
"        5 mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin",
"       </td>",
"       <td>",
"        2 g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aztreonam",
"       </td>",
"       <td>",
"        2&nbsp;g every 6 to 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefepime",
"       </td>",
"       <td>",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotaxime",
"       </td>",
"       <td>",
"        2&nbsp;g every 4 to 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftazidime",
"       </td>",
"       <td>",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        2 g every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloramphenicol",
"       </td>",
"       <td>",
"        1 to 1.5 g every 6 hours",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        400 mg every 8 to 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin",
"       </td>",
"       <td>",
"        1.7&nbsp;mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem",
"       </td>",
"       <td>",
"        2&nbsp;g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        400 mg every 24&nbsp;hours",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafcillin",
"       </td>",
"       <td>",
"        1.5 to 2&nbsp;g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxacillin",
"       </td>",
"       <td>",
"        1.5 to 2 g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin G potassium",
"       </td>",
"       <td>",
"        4 million units every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"       <td>",
"        600 mg every 24 hours",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobramycin",
"       </td>",
"       <td>",
"        1.7&nbsp;mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (cotrimoxazole)",
"       </td>",
"       <td>",
"        5 mg/kg every 6 to 12 hours",
"        <sup>",
"         &sect;&yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"       </td>",
"       <td>",
"        15 to 20 mg/kg every 8&nbsp;to 12 hours",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    MRSA: methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    <div class=\"footnotes\">",
"     * Dose based on ideal body weight or dosing weight, except in underweight patients. A calculator for ideal body weight and dosing weight is available in UpToDate.&nbsp;Dosage and interval must be individualized to produce a peak serum concentration of 7-9 mg/L and trough &lt;1-2 mg/L for gentamicin or tobramycin and a peak of 25-40 mg/L and trough &lt;4-8 mg/L for amikacin. For additional information, see the topic review on aminoglycosides.",
"     <br>",
"      &bull;&nbsp;The higher dose is recommended for patients with pneumococcal meningitis.",
"      <br>",
"       &Delta;&nbsp;No data on optimal dosage needed in patients with bacterial meningitis.",
"       <br>",
"        &loz;&nbsp;For the treatment of MRSA meningitis, the Infectious Diseases Society of America (IDSA)&nbsp;suggests a rifampin dose of 600 mg orally once daily or 300 to 450 mg twice daily.",
"        <sup>",
"         [1]",
"        </sup>",
"        <br>",
"         &sect;&nbsp;Dosage is based on the trimethoprim component.",
"         <br>",
"          &yen;&nbsp;For the treatment of MRSA meningitis, the IDSA suggests a trimethoprim-sulfamethoxazole dose of 5 mg/kg (based on the trimethoprim component) IV twice or three times daily.",
"          <sup>",
"           [1]",
"           <br/>",
"          </sup>",
"          &Dagger;&nbsp;The vancomycin dose should not exceed 2 g per dose or a total daily dose of 60 mg/kg.&nbsp;Adjust dose to achieve vancomycin serum trough concentrations of 15 to 20 mcg/mL.",
"          <sup>",
"           [1]",
"          </sup>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.",
"     <br>",
"      <em>",
"       Additional data from:",
"       <br/>",
"      </em>",
"      [1] Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary. Clin Infect Dis 2011; 52:285.",
"     </br>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5310=[""].join("\n");
var outline_f5_11_5310=null;
var title_f5_11_5311="Sinus arrhythmia child";
var content_f5_11_5311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Sinus arrhythmia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 74px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This rhythm strip shows a variation in the heart rate with gradual slowing and speeding up of the rate, which correlated with changes in the respiratory rate. Also note that p wave axis is consistent with a sinus origin (upright in lead II).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Andrew D Blaufox.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_11_5311=[""].join("\n");
var outline_f5_11_5311=null;
